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SELF-EMULSIFIED NANOEMULSION AS PERMEATION ENHANCER AND ITS 
APPLICATION FOR INTRANASAL DELIVERY OF INSULIN 
                                                                                  Kanyaphat Bunchongprasert 
  
This study aimed to investigate the permeation enhancing property and safety of 
self-emulsified nanoemulsion (SEN) and use these findings to enhance insulin absorption 
through the nasal route.  
The first part of the project was to identify the factors affecting cytotoxicity and 
permeation enhancement of SEN on Madin-Darby Canine Kidney (MDCK) cells, a 
widely used paracellular model. Twenty-six fatty acid esters (FAEs) commonly used in 
SEN were investigated. Among the FAEs (mono-, di-, and triesters), fatty acid 
monoesters (FAME) are the main excipient causing cytotoxicity and opening tight 
junction. The cytotoxicity of FAME in SEN was reduced with the presence of 
triglycerides, the increase in droplet size, and the higher intermolecular interaction within 
the lipid droplets.  
Then, the SENs consisted of various FAMEs, medium-chain triglyceride and 
Kolliphor®RH40 (1:1:2) were evaluated for their capability to enhance insulin across 
human airway epithelium cell (Calu-3) monolayer. The SENs containing medium-chain 
monoglyceride, G8/10MD (C8/C10 mono/diglycerides) showed the greatest permeability 
enhancement on insulin across the Calu-3 monolayer. The opening of the tight junction 
was reversible. Also, the SEN containing G8/10MD (SEN-G8/10MD) could prevent the 
fibril formation of insulin.  
 
 
Therefore, SEN-G8/10MD was selected for the ex vivo and in vivo studies. SEN-
G8/10MD (0.8-30%) had droplet size of 31±9 nm, polydispersity index of 0.065±0.031 
and zeta potential of -1.86±0.74 mV. The permeability of insulin across the ex vivo 
bovine nasal mucosa was significantly (p<0.05) increased by SEN-G8/10MD at 20% of 
the preconcentrate with a minimum nasociliotoxicity observed. In vivo study in 
streptozotocin-induced diabetic rats showed that as compared to subcutaneous injection, 
the relative pharmacodynamics availability achieved by SEN-G8/10MD at 20%, 10%, 
and 5% of the preconcentrate were 79.5%, 58.4% and 42.0%, respectively, significantly 
higher (p<0.05) than the 1.4% by the solution form. The three SENs also achieved the 
relative bioavailability of 37.9%, 19.3% and 8.8%, respectively, and the first two were 
significantly (p<0.05) higher than the 4.0% by the solution form. The SENs did not cause 
noticeable toxicity on the rats’ nasal epithelium.  
In conclusion, the SEN containing G8/10MD has a potential to deliver insulin 
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Self-emulsified nanoemulsion (SEN) spontaneously forms upon the dilution of a 
formulated preconcentrate, a combination of surfactant(s) and lipid(s) with or without 
cosolvents. SEN has been successfully adopted for some lipophilic drugs to enhance their 
absorption. For the main issue hindering lipophilic drugs from absorption is the 
extremely low aqueous solubility of these drugs. But these drugs can have significantly 
increased solubility in SEN due to a large amount of lipids and surfactants present in the 
formulation. Once they are in the solution form, these lipophilic drug molecules can 
easily diffuse through the absorption membrane via the transcellular route. However, it is 
a different case when dealing with hydrophilic drugs such as peptide/protein drugs. These 
drugs are usually poorly absorbed because they cannot diffuse through the absorption 
membrane via transcellular route for two reasons: the cell membrane is lipophilic and the 
drug molecular size usually is too large. It is well known that the main absorption route 
for these drugs is paracellular route, and the tight junction between the cells is the main 
obstruction for the paracellular absorption. 
How to open the tight junction and enhance the paracellular absorption have been 
extensively investigated for several decades. Many studies have demonstrated that most 
agents such as certain surfactants, bile salts, etc. which are able to open the tight junction 
exhibit certain toxicity on the cell membrane. The ideal case is that the agent opens the 
tight junction with minimum toxicity and the opening process is reversible.  
As early as in 2008, as the pilot study, our laboratory published several research 
papers on using SEN to deliver a model protein drug, -lactamase1-3. Since then, it has 
been seen in many publications from other research institutes on using SEN for 
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hydrophilic drugs with improved absorption. In recent years, our laboratory developed 
another SEN formulation for insulin intranasal delivery with 69% bioavailability relative 
to subcutaneous injection in rats. It can be inferred from these enhanced absorptions that 
the SENs could open the tight junction and enable these large and hydrophilic molecules 
to diffuse through the paracellular route, although several other mechanisms have also 
been proposed for the enhanced absorption.  
 Then come the questions: 1) which ingredients of the SEN formulation are 
effective in opening tight junction? 2) What is the safe concentration with minimum or 
acceptable toxicity? 3) Can the opening be reversed? and 4) How are these activities 
affected by the other ingredients in SEN and by the SEN properties such as droplet sizes? 
Literature search indicates that there lack of systemic investigations on these issues. 
 Therefore, the current project aims to answer these questions, particularly with the 
focus on fatty acid ester derivatives as the lipid and surfactants components of SEN, and 
also, based on these answers, to formulate a SEN for insulin, and further, to test its 
toxicity and absorption enhancement via in vitro, ex vivo and in vivo studies.      
Factors Affecting Cytotoxicity and Permeation Enhancement of SENs 
Most of the lipids and surfactants used to formulate SEN are amphiphilic, which 
comprises fatty acid(s) esterified with different hydrophilic head groups, called fatty acid 
ester derivatives (FAE). Literature indicates that many FAEs exhibit cytotoxic and 
permeation enhancing activities by disrupting the tight junctions to enhance paracellular 
transport 4, 5. Some of FAE structures including the numbers of chains and their chain 
length were reported affecting these activities. For example, Aungst et al. stated that 
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medium-chain triglycerides as permeation enhancers were much less effective than 
mono- and diglycerides4. Ujhelyi et al. showed that the permeability enhancement on 
lucifer yellow across the paracellular route of human colon carcinoma (Caco-2) by 
Tween®20 (C12) was higher than Tween®60 (C16) ≈ Tween®80 (C18:1, the number after 
colon indicates the number of double bonds), showing that the permeation enhancing 
effect of Tween® (FAE of PEGylated sorbitan) decreased with the increase in their chain 
length and also affected by the double bond6.  
However, Pabla et al. reported that the permeation enhancing effect of fatty acids 
increased with the increase in their chain length7, which was opposite to the Tween®s. 
The difference between fatty acids and FAEs is that the latter have larger hydrophilic 
head groups making them able to self-assemble to form micelles at the concentration 
higher than their critical micelle concentration (CMC)8. This indicates that the 
hydrophilic head group is another important structural factor of FAEs, and the micelle or 
droplet formation may affect FAE to interact with the cell membranes.  
In addition to the structural factors of FAEs on permeation enhancement of SEN, 
many factors have not been thoroughly investigated for the application of SEN for 
hydrophilic drugs such as the effect of droplet size, the interaction among excipients, etc. 
Therefore, the initial objective of the present study is to investigate factors affecting 
cytotoxicity and tight junction opening of SEN including 1) the numbers of fatty acid 
chains, 2) the presence of triglycerides, 3) the droplet size of SEN, and 4) the structures 
of FAEs, which are addressed in Chapter 1, where twenty-six FAEs with six hydrophilic 
head groups (propylene glycol, glycerol, sorbitan, polyethylene glycol, sucrose, and 
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PEGylated sorbitan) and various chain structures (number of chains, chain length, and 
number of double bonds) are investigated. 
Nasal Delivery of Insulin by SEN 
Insulin is a hydrophilic two-chain protein with 51 amino acids, three disulfide 
bonds, and a molecular weight of 5.8 kDa. As the result, there are various challenges for 
insulin to be delivered across non-invasive routes e.g. poor absorption across the 
lipophilic epithelium, susceptibility to proteolytic enzymes, and disulfide reductase, etc. 
Due to these challenges, the delivery of insulin remains as invasive dosage forms and a 
powder inhalation (Afrezza®) which causes potential side effects reducing patient 
compliance. Therefore, it is imperative to develop a safe and effective non-invasive 
delivery of insulin.  
Among non-invasive routes, the intranasal (i.n.) route has a great potential for 
insulin delivery such as the thinnest epithelium (50 µm), abundant vasculature structure, 
low enzymatic activity as compared to the rectal and intestinal routes, and avoiding first-
pass metabolism 9, 10. However, the permeability of insulin across the nasal epithelium is 
still low. The bioavailability of insulin solution following nasal administration to humans 
was below 1% 11. The mucociliary clearance also limits the retention time of the 
formulation on the nasal epithelium for about 15-20 min 12 and the ideal delivery volume 
per adult nostril is limited to about 0.2-0.3 mL 13, 14.  
A literature review shows that more than 50% of research articles have used the 
permeation enhancers to improve the bioavailability of i.n. insulin. However, many 
enhancers can cause damage to the nasal mucosa 10, 15, 16. SEN has been reported for its 
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safety and efficacy to enhance the bioavailability of many drugs through oral routes. But 
in addition to our previous studies on SEN for i.n. delivery of insulin, there is only one 
publication on SEN to deliver insulin by i.n. route reported by Sintov et al., showing a 
relative bioavailability of 21.5% from a w/o SEN consisted of 20% of water and 80% of 
other lipid excipients including surfactants, etc. 17. Such a high percentage of the lipid 
phase may cause several problems after nasal delivery, and the limited volume of water 
may not provide sufficient insulin dose for a human. It can be seen that the application of 
SEN on the nasal delivery of insulin has not been thoroughly studied.  
Therefore, the SEN developed in Chapter 1 is further evaluated for its efficacy 
and safety in delivering insulin through i.n. route by the means of in vitro cell culture, ex 
vivo bovine nasal mucosa, and in vivo diabetic rats, which are addressed in Chapters 2, 3, 





The objective of the present study is to investigate the permeation enhancing 
property and safety of SEN, particularly the FAEs when formulated in SEN, and use 
these findings to enhance insulin absorption through the nasal route. 
The specific objectives are as following: 
I. to identify the factors affecting cytotoxicity and permeation enhancement of 
SEN, particularly the FAEs when formulated in SEN; and develop a SEN for 
insulin;  
II. to evaluate the efficacy and toxicity of the developed SEN for the transport of 
insulin across cell monolayer in vitro; 
III. to investigate the efficacy and toxicity of the developed SEN for the transport 
of insulin across bovine nasal mucosa ex vivo; 
IV. to study the efficacy and toxicity of the developed SEN for i.n. delivery of 






FACTORS AFFECTING CYTOTOXICITY AND PERMEATION 
ENHANCEMENT OF SEN 
In this present study, twenty-six FAEs (Table 1) with six hydrophilic head groups 
including propylene glycol, glycerol, sorbitan, polyethylene glycol, sucrose, and 
PEGylated sorbitan (Table 2) and various chain structures (number of chains, chain 
length, and number of double bonds) were investigated for their cytotoxic and permeation 
enhancing effects of SEN formulations. Madin-Darby Canine Kidney (MDCK) cell line 
was used as the cell culture model since it exhibits tight junctions and has been widely 
used as a paracellular model with time-efficiency advantage18-24. 
1.1 Materials  
Captex®8000, Captex®1000, Captex®100, Capmul®PG12 EP/NF, Capmul®MCM 
C8, Capmul®MCM EP/NF, Capmul®808G EP/NF, and Capmul®GMO 50 EP/NF were 
kindly gifted by Abitec Corporation (Janesville, WI, USA). Soybean oil, Span®20, and 
Span®80 were purchased from Spectrum® Pharmaceuticals (Irvine, CA, USA). 
Kolliphor®EL and Kolliphor®HS15 were kindly gifted from BASF (Tarrytown, NY, 
USA). Labrafac™PG, Capryol™90, GELEOL™, PECEOL™, Maisine®CC, and 
Labrasol®ALF were kindly gifted from Gattefossé (Paramus, NJ, USA). Sucrose Laurate 
was kindly gifted from Mutchler Inc. (Lakewood, OH, USA). Kolliphor®RH40 and 
Tween®80 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Tween®20 and 
Dimethyl sulfoxide (DMSO) were purchased from VWR (West Chester, PA, USA). 
Tween®85 and 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazoliumbromide (MTT) were 
purchased from Thermofisher Acros Organics (Morris Plains, NJ, USA). Propylene 
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glycol monopalmitate and monostearate, and propylene glycol monostearate were 
purchased from TCI America (Portland, OR, USA) 
MDCK (NBL-2) cell line was purchased from ATCC® (Rockville, MD, USA). 
Dulbecco’s Modified Eagle Medium (DMEM), Dulbecco’s Phosphate-Buffer Saline, and 
penicillin-streptomycin solution were purchased from Hyclone (Logan, UT, USA). Fetal 
Bovine Serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, GA, 
USA). Mannitol, D-[1-14C], with 56.8 mCi/mmol, and Ultima Gold Scintillation cocktail 
were purchased from PerkinElmer (Boston, MA, USA). Trypsin (0.05%) with 0.53 mM 
ethylenediaminetetra acetic acid (EDTA) was purchased from Mediatech Inc. (Manassas, 
VA, USA).  
1.2 Methods 
1.2.1 Preparation and Characterization of SENs 
Table 1 shows the studied fatty acid esters (FAEs) and their abbreviations. The 
solid, semi-solid, and highly viscous excipients including SPEG18:1T, Kolliphor®RH40, 
G8M, G18:1/18:2MD, S18:1M, Kolliphor®HS15, PG16/18M, PG18M, and G16/18M 
were melted at the possible lowest temperature for weighing. 
Preconcentrates were specially formulated to investigate the effect of the numbers 
of fatty acid chains in SEN on cytotoxicity (Table 3), the effect of triglyceride in SEN 
and droplet sizes of SEN on cytotoxicity (Table 4), and the effect of the structure of fatty 
acid monoester (FAME) in SEN on cytotoxicity and tight junctions (Table 5). The 
preconcentrates were shaken in a MaxQ™4000 Orbital Shaker (Thermo Scientific™, 
MA, USA) for three hours (300 rpm, 50ºC), except the preconcentrate containing 
G16/18M was shaken at 65ºC. The preconcentrates were diluted with sterile DMEM to 
form SENs at various concentrations. The preparation was done under aseptic conditions 
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and the SENs were freshly prepared for each experiment. The droplet size of the SENs 












Fatty Acid Tri-esters 
Glyceryl Tricaprylate 
Captex®8000 C8 Triesters G8T ≤ 1 
Glyceryl Tricaprate 
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PG Dicaprate  Captex®100 C10 Diesters PG10D ≤ 1 
PG Monocaprylate  





PG Monolaurate  






















































Glyceryl Monooleate  PECEOL™ 
C18:1 
Monoester 













Fatty Acid Ester of Sorbitan (S)  

























Fatty Acid Ester of Sucrose (SC)  



















a: the number after the colon indicates the number of double bonds; b: Primarily contains 
monoester, but also contains a certain amount of di- and tri-esters; c: reported by 
Gattefossé; d: reported by Abitec  
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Table 2 Structure of hydrophilic functional group of fatty acid esters. 
  
Chemical name Structure 






























Table 3 SEN formulations for the study of effect of the numbers of fatty acid chains in 
SEN on cytotoxicity (mean ± SD, n =3).  

















FAE and Kolliphor®RH40 at 1:4 (w/w) 
G8T 27 ± 6 0.055 ± 0.021 
G18:1/18:2T 25 ± 10 0.135 ± 0.039 
S18:1T 21 ± 6 0.074 ± 0.018 
SPEG18:1T 20 ± 3 0.095 ± 0.043 
PG8/10D 21 ± 4 0.094 ± 0.022 
PG10D 20 ± 7 0.056 ± 0.020 
PG8M 15 ± 3 0.010 ± 0.004 
G8/10MD 15 ± 3 0.009 ± 0.004 
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Table 4 SEN formulations for the study of effect of triglyceride in SEN and droplet sizes 









G18T: G8/10MD (7:3) 1:1 257 ± 112 0.265 ± 0.056 
G8T: G8/10MD (1:1) 1:1 30 ± 9 0.068 ± 0.008 
G8/10MD 1:1 120 ± 94 0.310 ± 0.063 
G8/10MD 1:4 15 ± 3 0.009 ± 0.004 














Table 5 SEN formulations for the study of effect of structure of fatty acid monoester 
(FAME) in SEN on cytotoxicity and tight junctions (mean ± SD, n =3). 
a: 2% (w/v) of the preconcentrate in DMEM. 
  




Fatty acid monoester (FAME), G8T, and Kolliphor®RH40 at 1:1:2 (w/w) 
PG8M 37 ± 18 0.076 ± 0.031 
PG12M 42 ± 16 0.155 ± 0.038 
PG16/18M Phase separated N/A 
PG18M Phase separated N/A 
G8MD 28 ± 5 0.027 ± 0.015 
G8/10MD 29 ± 4 0.031 ± 0.015 
G8M 28 ± 4 0.034 ± 0.021 
G16/18M Phase separated N/A 
G18:1M 36 ± 0 0.164 ± 0.040 
G18:1/18:2MD 49 ± 22 0.365 ± 0.078 
G18:2MD 38 ± 14 0.104 ± 0.035 
PEG8/10MD 29 ± 8 0.034 ± 0.011 
S12M 26 ± 7 0.038 ± 0.021 
S18:1M 34 ± 13 0.099 ± 0.032 
SC12M 36 ± 20 0.205 ± 0.043 
SPEG12M 26 ± 10 0.184 ± 0.071 
SPEG18:1M 27 ± 9 0.121 ± 0.054 
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1.2.2 Cell Culture 
The MDCK cells were cultured in the T-75 flasks in the culture medium 
(cMedium) containing DMEM (with phenol red), 10% FBS, and 1% penicillin-
streptomycin solution at 37ºC with 5% CO2/95% air. The cells were split and subcultured 
when reached 80% confluence. 
1.2.3 Cytotoxicity Study 
The MDCK cells were seeded to the 96-well plates at the density of 7000 
cells/well in 200 µL cMedium. The cells growing for two days were washed once with 
DMEM. Then 200 µL of cMedium, DMEM, 4% Kolliphor®RH40 in DMEM, or SENs of 
various concentrations of the preconcentrates were added to each well (n=6) and 
incubated at 37oC for two hours. The samples were removed and the cells were washed 
once with cMedium. Then, the MTT solution (200 µL, 2.5 mg/mL in cMedium) was 
added to each well, and the plates were further incubated for two hours. The MTT 
solution was removed and replaced with DMSO (200 µL), and the plates were covered 
with foil to protect from the light exposure. The plates were agitated for five min and the 
absorbance of formazan in each well was analyzed by a UV spectrophotometer at 560 
nm. The cell viability (%) was calculated based on the absorbance and with the cells 
treated with cMedium as 100% cell viability.  
1.2.4 Effect of SENs on Tight Junctions 
The MDCK cells in cMedium at the density of 6.5 x 104 cells/cm2 were seeded on 
the Transwell® insert with a surface area of 4.6 cm2/well and membrane pore size of 0.4 
µm and incubated at 37oC. The culture media was changed every other day for four days 
and then every day for three more days. The TEER value was monitored to measure the 
formation of the tight junction. Confluent cell monolayers with the TEER value higher 
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than 180 Ω.cm2 were washed with DMEM twice. Then fresh DMEM (2.5 mL) was added 
to the receiver chamber, and 1.5 mL of the DMEM, 4% Kolliphor®RH40 in DMEM, or 
SENs of various concentrations of the preconcentrates (Table 3-5) were added to the 
donor chamber (n=3), and further incubated for two hours. TEER value was measured at 
the beginning and every hour during the transport study. 
1.2.5 Recovery of Tight Junctions Integrity Pretreated with SENs 
The monolayers pre-treated with SENs were washed with cMedium twice and 
incubated for twenty-four hours in cMedium. Then, the cMedium in the donor chamber 
was removed and replaced with cMedium containing one µL/mL of mannitol, D-[1-14C], 
used as the paracellular transport marker. The monolayers were further incubated for two 
hours. Samples (0.2 mL) were taken from the receiver chamber for radioactivity assay. 
The TEER value was measured at 1, 2, 4, 6, 24, and 26 hours of the recovery period. The 
apparent permeability coefficient (Papp) of 
14C-mannitol was calculated from the 





where Papp is the apparent permeability coefficient (cm/s), Q is the total 
radioactivity permeated throughout the incubation time (DPM, Disintegration per min), A 
is the surface area of the Transwell® Insert (4.6 cm2), C0 is the initial radioactivity of the 
marker in the donor chamber (DPM/cm3), and t is the total time of the permeation (min).  
1.2.6 Quantification of Radioactivity 
The samples taken from the recovery study (0.2 mL) were mixed with Ultima 
GoldTM scintillation cocktail (3 mL) in a 7-mL scintillation vial. Then, the disintegrations 
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per min (DPM) of the radioactive (14C) was counted by a Tri-carb Liquid Scintillation 
Analyzer Model B3110 TR (PerkinElmer, CT, USA). 
1.2.7 Statistical Analysis 
The data are expressed as mean ± standard deviation (n=6 for cell viability, and 
n=3 for other studies). The viability was analyzed by one-way ANOVA and the transport 
of marker was analyzed by the student’s t-test to compare the difference between the 







1.3 Results and Discussion 
1.3.1 Cytotoxicity of Surfactants 
The cytotoxicity of FAEs’ micelles was first studied to understand the effect of 
the corresponding FAE structure alone. The five FAEs commonly used as surfactants for 
SEN were investigated: Kolliphor®RH40, Kolliphor®EL, Kolliphor®HS15, Tween®80 
(SPEG18:1M), and Tween®85 (SPEG18:1T). The concentration used was in the range of 
0.25-5.00%, higher than the reported CMCs. The reported CMCs of Kolliphor®RH40, 
Kolliphor®EL, and Kolliphor®HS15 was 0.039%, 0.010%, and 0.018%, respectively25, 26, 
and that of Tween®80 (SPEG18:1M) and Tween®85 (SPEG18:1T) was 0.0014% and 
0.0023%, respectively27.  
The comparison of the cytotoxicity results was divided into two groups based on 
the structural similarity of the FAEs: 1) Kolliphor®RH40, Kolliphor®EL, 
Kolliphor®HS15, and 2) Tween®80 (SPEG18:1M) and Tween®85 (SPEG18:1T). 
Figure 1A shows the viability of MDCK cells after exposure to Kolliphor®RH40 
at the concentration range of 0.25-5.00% (w/v) in DMEM. There was no reduction in 
viability after the 2-h exposure, but the viability after 3-h exposure was decreased to 
57.38 ± 10.83% and 39.49 ± 3.59% by 4% and 5% of Kolliphor®RH40, respectively. 
These results demonstrate that the cytotoxicity caused by Kolliphor®RH40 was both 
time- and concentration-dependent. Therefore, the other cytotoxicity studies and transport 
studies were limited to two hours to eliminate the cytotoxicity caused by 
Kolliphor®RH40. 
Kolliphor®EL had a similar effect on the cell viability as Kolliphor®RH40 
(Fig.1b): the viability was higher than 90% after the 2-h exposure. This was due to the 
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two have a similar structure. Kolliphor®HS15 caused the concentration-dependent 
reduction in the cell viability after 2-h exposure (Figure 1B). There are two differences 
between Kolliphor®HS15 and Kolliphor®RH40: 1) the numbers of hydroxystearate 
chains; and 2) the hydrophilicity of the head group, although both have the similar HLB 
value of 15. Kolliphor®HS15 is a mixture of mono- and di-esters of hydroxystearate, 
which has less lipid chain compared to Kolliphor®RH40 (three chains). This causes less 
intermolecular attraction through the non-polar tails. Further, Kolliphor®HS15 has a 
smaller head group (PEG-15) than Kolliphor®RH40 (PEG-40), which further reduces the 
intermolecular attraction through the polar heads. Therefore, the monomers of 
Kolliphor®HS15 are easier to diffuse out from the micelles than Kolliphor®RH40, which 
would have more interaction with the cell membrane to cause higher cytotoxicity. Maher 
et al. proposed that it is the monomers which diffuse out from micelles would interact 
with the cell membrane to cause cytotoxicity28.  
SPEG18:1T did not show any cytotoxicity at the studied concentration range, 
whereas SPEG18:1M showed a concentration-dependent reduction in the cell viability 
(Fig. 1b). The only difference between SPEG18:1T and SPEG18:1M is the number of 
oleate chain (C18:1). The three nonpolar chains in SPEG18:1T caused higher 
intermolecular binding as compared to only one chain in SPEG18:1M, which was 
correlated to the higher cytotoxicity by Kolliphor®HS15 (one and two chains) as 































































Figure 1 Cytotoxicity: (A) Kolliphor®RH40 in DMEM at two hours (Solid line), and 
three hours (Dashed line) (mean ± SD, n=6); (B) Kolliphor®EL (■, solid line), 
Kolliphor®HS15 (■, dashed line), SPEG18:1T (△, solid line), and SPEG18:1M (△, 






1.3.2 Preparation and Characterization of SENs  
 The droplet size of SEN containing mono-, di-, or tri-esters of fatty acid with 
Kolliphor®RH40 (1:4) was presented in Table 3. These SENs were formulated to study 
the effect of the number of fatty acid chains (one, two, and three chains) on the 
cytotoxicity of FAEs in SEN. The mean droplet size of these SENs was below 30 nm.  
Table 4 presents the composition of the preconcentrates of various SENs and their 
droplet size which were formulated to study the effect of triglyceride and droplet size on 
the cytotoxicity of G8/10MD in SEN. The mean droplet size of SEN containing 
G8/10MD, G18:1T, and Kolliphor®RH40 (7:3:10) was 257 nm, larger than 140 nm, 
which should be classified as an emulsion29. The SEN containing G8/10MD, G8T, and 
Kolliphor®RH40 (1:1:2) had the mean droplet size of 30 nm. The SEN containing only 
G8/10MD and or®RH40 at 1:1 and 1:4, without triglycerides, had the mean droplet size 
of 120 and 15 nm, respectively.  
Table 5 shows the droplet size of the studied SENs containing FAMEs which 
were formulated to study the effect of the structural factors of FAMEs on their 
cytotoxicity in SEN and opening of tight junctions. The preconcentrates containing 
saturated long-chain FAMEs including PG16/18M, PG18M, and G16/18M caused phase 
separation when diluted with DMEM. Therefore, these FAMEs were excluded from 
further studies. All other SENs containing FAMEs had the mean droplet size below 50 
nm. 
1.3.3 Cytotoxicity of SENs 
The reduction in the cell viability caused by SENs was found to depend on four 
different factors: 1) the numbers of fatty acid chains, 2) the presence of triglycerides, 3) 
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the droplet size, and 4) the structures of fatty acid monoester (FAME). Figure 2-4 show 
the cell viability after the 2-h exposure to the various SEN formulations. 
1.3.3.1 Effect of Numbers of Fatty Acid Chains on the Cytotoxicity of 
Fatty Acid Ester in SENs 
The above micelle results (Section 1.3.1) show that the compounds exhibiting 
high cytotoxicity were either monoester (SPEG18:1M) or the mixture of mono- and di-
ester (Kolliphor®HS15). Therefore, other FAEs (tri-, di-, or monoester of glycerol and 
propylene glycol) were studied to further investigate the effect of the number of fatty acid 
chains when formulated in SENs. The concentration of SENs used in this study was 4% 
(0.8% of tri-, di-, or monoester and 3.2% of Kolliphor®RH40). There was no noticeable 
reduction in the cell viability caused by Kolliphor®RH40, the SENs containing FAE with 
three chains (G8T, G10T, or G18:1/18:2T), or the SENs containing FAE with two chains 
(PG8/10D, or PG10D). However, the SENs containing FAEs with one chain (PG8M or 
G8/10MD) decreased the cell viability to 9.05±1.64% and 5.11±0.09%, respectively 
(p<0.01). (Figure 2). These results indicate that fatty acid monoester (FAME; one chain) 





Figure 2 Cytotoxicity of controls (Pattern fill) and SEN containing FAEs (Solid fill). 
Black bar: SEN containing fatty acid triesters (three chains); Grey bar: SEN containing 
fatty acid diester (two chains); White bar: SEN containing fatty acid monoester (one 



























1.3.3.2 Effect of Triglyceride on the Cytotoxicity of Fatty Acid 
Monoester in SEN 
This study aims to investigate whether the presence of triglyceride would alter the 
cytotoxicity of fatty acid monoester (FAMEs) in SEN. From Section 1.3.3.1, the viability 
was found to decrease with the presence of FAMEs (PG8M or G8/10MD). Therefore, 
G8/10MD was selected to formulate SENs with and without triglyceride. Two 
triglycerides were used including G18:1T or G8T, and Kolliphor®RH40 was used as the 
surfactant. Four SEN formulations were formulated (Table 4). The first two SENs were 
SENs containing triglycerides (G18:1T or G8T), and the other two SENs were SENs 
without triglycerides. These four SENs were diluted at various dilutions to prepare SENs 
which contain the same concentration of G8/10MD. 
Figure 3 demonstrates the relationship between the concentration of G8/10MD in 
each SEN and the cell viability after 2-h exposure to the corresponding SENs. At the 
concentration of G8/10MD from 0.05% - 0.25%, the cell viability reduced by SENs 
without triglycerides significantly (p<0.05) lower than the viability reduced by SENs 
containing triglycerides. For example, at 0.05% of G8/10MD, SENs without triglycerides 
reduced the cell viability to 50-60%, whereas SENs containing triglycerides resulted in 
the cell viability higher than 100%. Similarly, when the concentration of G8/10MD in 
SENs was 0.15%, SENs without triglycerides decreased the viability to below 10%, 
whereas SENs containing triglycerides resulted in the viability of 80-100%. 
These results show that the presence of C8 and C18:1 triglycerides (G8T and G18:1T, 
respectively) in the SEN formulation can reduce the toxicity of FAME (G8/10MD). And 
this may be because the addition of triglycerides in the SENs increases the intermolecular 
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interaction in the lipid droplets which may help to retain G8/10MD monomers within the 




























Concentration of G8/10MD in SEN (%)
G8/10MD: G18:1T: RH40 (3:7:10, 260 nm)
G8/10MD: G8T: RH40 (1:1:2, 30 nm)
G8/10MD: RH40 (1:1, 120 nm)





















Figure 3 Cytotoxicity of G8/10MD in SENs containing triglycerides either G18:T or 
G8T (Solid fill) and SENs without triglyceride (Pattern fill) (mean ± SD, n=6). *: 
Significantly lower than SEN containing triglycerides (p<0.05).  





1.3.3.3 Effect of Droplet Size of SEN on the Cytotoxicity of Fatty Acid 
Monoester in SEN  
In addition to the effect of triglyceride, the effect of the droplet size of SEN was 
also investigated whether the difference in SEN’s droplet size would alter the cytotoxicity 
of fatty acid monoester (FAMEs) in SEN. Four SENs containing G8/10MD described in 
Table 4 were also used in this study.  
The SEN containing triglycerides were formulated to have different droplet sizes.  
SEN containing G8/10MD, G18:1T, Kolliphor®RH40 (3:7:10) had the droplet size of 260 
nm, whereas the droplet size of SEN containing G8/10MD, G8T, Kolliphor®RH40 
(1:1:2) was 30 nm. Figure 4A demonstrates the comparison between 260-nm and 30-nm 
SEN containing triglycerides. At 0.25% and 0.3% G8/10MD, the cell viability reduced by 
30-nm SEN was significantly (p<0.05) lower than 260-nm SEN (47.89 ± 5.13% vs 
137.78 ± 40.24% and 8.44 ± 0.46% vs 72.24 ± 17.25%, respectively).  
The SEN without triglycerides were also formulated to have different droplet 
sizes. The SEN containing G8/10MD and Kolliphor®RH40 (1:1) had the droplet size of 
120 nm, while SEN containing G8/10MD and Kolliphor®RH40 (1:4) had the droplet size 
of 15 nm. Figure 4B shows the comparison between 120-nm and 15-nm SEN without 
triglycerides. At 0.075% of G8/10MD, the cell viability reduced by 15-nm SEN was 
significantly (p<0.05) lower than 120-nm SEN (16.26 ± 5.23% vs 48.48 ± 14.12%).  
It can be concluded that the toxicity of G8/10MD in lipid droplets was higher with 
the smaller droplet sizes. This may be due to 1) smaller lipid droplets have a larger 
surface area than bigger lipid droplets at the same concentration, leading to more contact 
30 
 
between the cells and G8/10MD; and 2) the diffusion of G8/10MD is easier from smaller 

























Concentration of G8/10MD in SEN (%)
G8/10MD: G8T: RH40 (3:7:10, 260 nm)






















Concentration of G8/10MD in SEN (%)
G8/10MD: RH40 (1:1, 120 nm)


























Figure 4 Cytotoxicity of G8/10MD in SEN with the same compositions but difference in 
droplet size. (A): the comparison between 260-nm and 30-nm SEN containing G8/10MD 
with triglycerides and Kolliphor®RH40; (B): the comparison between 120-nm and 15-nm 
SEN containing G8/10MD and Kolliphor®RH40 (mean ± SD, n=6). *: Significantly 








1.3.3.4 Effect of Structures of Fatty Acid Monoester on their 
Cytotoxicity in SEN 
SENs containing various FAMEs were further formulated (G8T: FAME: 
Kolliphor®RH40 =1:1:2) to examine the other factors of FAMEs such as chain length, 
hydrophilic head group, and number of the double bond in the chain. As a result of 
section 1.3.3.2 and 1.3.3.3, the addition of G8T in SEN was performed to minimize the 
toxicity of FAMEs and the droplet size of all SEN containing FAMEs was formulated to 
be below 50 nm in order to avoid any complication caused by the difference in size.  
Figure 5 shows the cytotoxicity of the cell monolayer exposed to SENs containing 
various FAMEs. The SENs containing medium-chain FAME of glycerol and propylene 
glycol (HLB 4-7) resulted in <10% cell viability, while the SENs containing medium-
chain FAME of sorbitan, PEG-8, sucrose, and PEGylated sorbitan (HLB>8) resulted in 
cell viability of 80-129%. The structural difference between the two groups of FAMEs is 
the latter has a bigger hydrophilic head group. These results indicate that the increase in 
hydrophilicity of the head groups equal or greater than sorbitan can reduce the 
cytotoxicity of FAME, which may be due to 1) the stronger interaction between the larger 
head group helps to maintain the monomer within the droplets, and 2) the more 
hydrophilic monomers in the medium trend to self-assembling rather than perturbating to 
the cell lipophilic membrane. 
The SENs containing the long-chain FAMEs with a single double bond (G18:1M, 
S18:1M, and SPEG18:1M) resulted in no noticeable cytotoxicity, while the SENs 
containing the long-chain FAMEs with two double bonds (G18:1/18:2MD and 
G18:2MD) reduced the cell viability to 46% and 18%, respectively. These results indicate 














































Figure 5 Cytotoxicity of fourteen fatty acid monoesters (FAMEs) in SEN. Grey bar: 




1.3.4 Effect of SENs on Tight Junction  
1.3.4.1 TEER Reduction  
Transepithelial electrical resistance (TEER) measurement has been widely used to 
assess the integrity of tight junctions. The reduction in TEER value is an indicator of 
compromised tight junctions altering the paracellular permeability of epithelium. Figure 6 
shows the change in TEER value of the monolayer pretreated with SENs for two hours. 
The TEER of the monolayers pretreated with the SENs containing only G8T and 
Kolliphor®RH40 (1:4), or PG10D and Kolliphor®RH40 (1:4) at 4% (w/v) was constant 
after two hours indicating the intact tight junction integrity. The TEER reduced by the 
SENs containing PEG8/10MD, S12M, SC12M, and SPEG12M was only 76-89%. 
However, the presence of medium-chain FAME of glycerol or propylene glycol reduced 
the TEER to approximately 30%. These results demonstrate that the medium-chain 
FAME of glycerol or propylene glycol (HLB 4-7) had a higher effect on tight junction 
opening than the medium-chain FAME of PEG-8, Sorbitan, Sucrose, and PEGylated 
sorbitan (HLB>8), which was correlated to their cytotoxicity effects. 
The SENs containing the long-chain FAMEs with a single double bond (G18:1M, 
S18:1M, and SPEG18:1M) resulted in no reduction in TEER, while the SENs containing 
the long-chain FAMEs with two double bonds (G18:1/18:2MD and G18:2MD) reduced 
the TEER to 61% and 72%, respectively. This indicates that long-chain FAMEs with two 
double bonds have a higher effect on tight junction opening than the other long-chain 
FAMEs. And similar to medium-chain FAMEs, there was a correlation between the 
TEER reduction and cell viability.  
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1.3.4.2 Mechanism of Action  
Maher et al. stated that when FAE formed micelles, the FAE monomers diffusing 
out from its micelles to interact with the cell phospholipid bilayers, which consequently 
alters the cell membrane integrity5, 28. Therefore, intermolecular attraction force between 
the FAEs, and FAE with other excipients, plays a key role in determining the diffusion of 
the FAE monomers out of the lipid droplets to interact with the epithelial layer.  
One of the parameters indicating the intermolecular binding force of FAME 
molecules is the melting point. The melting point of G18M, G18:1M, G18:1/18:2MD, 
and G18:2MD is 54-64˚C, 24˚C, 14-19˚C, and < 0 ˚C, respectively30. The presence of 
double bond decreases the melting point which is corresponding to the decrease in 
intermolecular attraction29, 31. The strong intermolecular attraction of the saturated long-
chain FAMEs makes these molecules binding together and unable to be dispersed by the 
emulsifier to form nanodroplets. FAME molecules with double bond have less 
intermolecular attraction and are easier to be mixed and incorporated into the droplets 
with the emulsifier. Further, because of the lower intermolecular attraction, the 
monomers with double bond are easier to escape from the droplets and to interact with 
the tight junctions to enhance the permeability. The more double bonds, the bigger such 
effects.  
The melting point of G8MD, G10MD, G12M, G18M (all with saturated chain) is 
30-34˚C, 40-41˚C, 56-60˚C, 54-64˚C, respectively, indicating that the longer the chain 
length the higher the intermolecular attraction30. Due to this reason, FAME monomers 
with shorter chain-length can diffuse easier out of the lipid droplets and cause higher 
cytotoxicity and permeation enhancement.  
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However, the interactions of the FAMEs with the cellular membrane not only 
depend on their chain length but also depend on the structure of the chain (saturated vs 
unsaturated). The medium-chain FAMEs (G8M, G8MD, and G8/10MD) had higher 
cytotoxicity and effect on tight junctions than the long-chain FAMEs with double bond(s) 
(G18:1M, G18:1/18:2MD, and G18:2MD), even though the formers have a higher 
melting point (higher intermolecular attraction) than the latter. Because the presence of 
double bond kinks in the hydrocarbon tail32, this may make the monomers difficult to 
interact with tight junctions. As a result, the presence of double bonds in the long-chain 
FAME increases the monomer diffusion out of the lipid droplets, but reduces the 
monomer interaction with tight junctions.  
In conclusion, both intermolecular attraction and structure of FAMEs influence 
their cytotoxicity and effect on the tight junction. The intermolecular attraction among 
FAMEs in the lipid droplets determines how easy the FAME to diffuse out of the 
droplets, while the structure of the FAME determines its interaction with the tight 
junctions. FAMEs with less intermolecular attraction than di- and tri-esters had more 
cytotoxic and higher interaction with tight junctions. Among the FAMEs, the degree of 
these effects are in the following order: medium-chain with small hydrophilic head (PG 
and G) > long-chain with two double bonds > medium-chain with large head (S, PEG, 
SC, and SPEG) ≈ long-chain with single double bond > saturated long-chain, which are 
consistent with the intermolecular attraction force (low-high) of the various FAEs. And 
the more kinks in the monomer’s tail caused by the double bond, the less the monomer to 



























Fatty acid monoesters in SEN




















Figure 6 Change in TEER of the MDCK monolayer after the 2-h exposure to SEN 
containing fourteen FAMEs (Solid fill) and after 24-h recovery (Pattern fill). Black bar: 








1.3.5 Recovery of Tight Junctions Integrity Pretreated with SENs 
14C-Mannitol is a commonly used paracellular transport marker because it usually 
permeates passively through the paracellular route 33. Figure 6 and 7 present the TEER 
value and the Papp of 
14C-mannitol across the monolayer recovered for twenty-four hours 
after the 2-h exposure to SENs containing FAMEs, respectively. The Papp of 
14C-mannitol 
across the monolayer pre-treated with the SENs containing PG8M, PG12M, G8MD, 
G8/10MD, G8M was about 10 times higher than the control (p<0.05), and the TEER of 
these monolayers remained as only about 30% after the 24-h recovery period. The 
increase in mannitol permeability confirmed the effect of SEN containing FAME on 
paracellular permeability. The Papp of 
14C-mannitol across the monolayer pre-treated with 
the SENs containing PEG8/10MD and SC12M were also increased for 2.4 and 1.8-fold, 
while SENs containing S12M and SPEG12M had similar mannitol transport, as 
compared to the control.   
The recovery of the monolayers pretreated with the SEN containing medium-
chain FAMEs of small heads (glycerol or propylene glycol) was much less than the 
monolayers pretreated with the SENs containing medium-chain FAMEs of larger heads 
(PEG-8, Sorbitan, Sucrose, and PEGylated sorbitan). This result together with the results 
of cytotoxicity confirms that the large head group of the FAME increases the 
intermolecular attraction between the heads and thus restrains the diffusion of the FAME 
monomers out of the droplets to interact with the cell monolayer. 
There was no significant (p>0.05) difference in the Papp of 
14C-mannitol through 
the monolayers pre-treated by S18:1M and SPEG18:1M compared to the control. But the 
monolayer pre-treated with G18:1M, G18:1/18:2MD, and G18:2MD exhibited a 
significant (p<0.05) increase in the transport of 14C-mannitol for 1.7, 1.8, and 3.6 folds as 
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compared to the control, respectively. These results demonstrate that the long-chain 
FAMEs with smaller hydrophilic heads and more double bonds had more effect on 



















































Figure 7  Transport of 14C-Mannitol through the MDCK cell monolayer recovered for 
twenty-four hours after the 2-h exposure to SEN containing FAMEs. Black bar: controls; 
Grey bar: medium-chain FAMEs; White bar: Long-chain FAMs (mean ± SD, n=3). *: 
Significant increase compared to the monolayer pre-treated with DMEM (p<0.05). 
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1.4 Trends and Limitations 
Literature reviews show that medium-chain fatty acids (MCFA) exhibit a 
capability to modulate the localization or conformation of occludin and ZO-1 which are 
the essential protein components of tight junctions 34. The modulation of these adhesion 
proteins results in the reduction in TEER and selectively alters the paracellular 
permeability of the epithelial membrane. MCFA is also reported to inhibit phospholipase 
C-dependent pathway35. Ward et al. demonstrated that the inhibition of phospholipase C-
beta in MDCK cell monolayer can lead to an increase in paracellular permeability by the 
disorganization of actin filaments36. The interaction between occludin protein and long-
chain fatty acids (LCFA) was also observed by Jiang et al. resulted in the reduction in 
TEER37, 38. Oleic acid (C18:1) did not modulate the tight junction proteins, but it was 
found to increase protein kinase C and disperse into lipid bilayer which also induced the 
paracellular permeability37, 39, 40.    
The TEER results in this study show that fatty acid monoester (FAME) in SEN 
can also interact with the tight junctions. However, there has been limited investigation of 
the effect of fatty acid ester (FAE) on tight junctions, especially FAME. To the best 
knowledge of the authors, only Labrasol (PEG8/10MD) and sucrose laurate (SC12M) 
which are FAME reported to exhibit to capability to open the tight junctions through the 
localization or conformation of occludin and ZO-1 proteins41, 42.    
The TEER reduction found with medium-chain FAMEs and long-chain FAMEs 
with two double bonds was correlated to the effect of MCFA and LCFA reported in the 
previously mentioned literature. It can be inferred that SEN containing FAME can 
enhance paracellular permeability by compromising the tight junctions through the 





Among the FAEs (mono-, di-, and triesters), the fatty acid monoester (FAME) is 
the main excipient causing concentration-dependent cytotoxicity and opening of tight 
junction. When FAME was formulated in SEN, the cytotoxic of FAME is reduced with 
the presence of triglycerides, the increase in droplet size, and the higher intermolecular 
interaction within lipid droplets.  
Therefore, four FAMEs (G8/10MD, G18:1M, G18:2MD, and PEG8/10MD) 
which exhibit capability to open tight junctions and consist of various structural factors 
were selected to formulate SENs with triglyceride and evaluated for its efficacy and 





IN VITRO EVALUATION OF SEN CONTAINING FATTY ACID MONOESTERS 
FOR NASAL DELIVERY OF INSULIN 
From Chapter 1, SEN containing FAMEs could open the tight junctions of the cell 
monolayer. Therefore, in this present study, SENs containing FAMEs were further 
evaluated for their capability to enhance insulin across the opened tight junctions, in 
vitro. One of the concerns, when insulin is in the aqueous phase of SEN, is that insulin 
being a natively structured amyloidogenic protein can aggregate and form fibril or 
filament. The formation of fibrils reduces insulin bioactivity. Nielssen et al. explained 
that nucleation and fibril growth of insulin molecule can be controlled by hydrophobic 
and electrostatic interactions. Also, some of the excipients e.g. sucrose, Trimethylamine 
N-oxide (TMAO), quinone, etc. have been reported for their ability to stabilize and 
prevent insulin aggregation 43-45. Therefore, SEN which contains surfactant and co-
surfactant may also prevent the fibril formation of insulin. 
The human airway epithelial cells (Calu-3), an adenocarcinoma cell line derived 
from Caucasian males, can form a monolayer with a mucus layer and functional tight 
junctions, desmosomes, and zonular adherence 46, 47. Both MDCK and Calu-3 have an 
ability to form monolayer with tight junctions and are a good model for paracellular 
transport47. However, only Calu-3 exhibits the mucus layer which can better mimic the 
nasal epithelium than MDCK. The mucus layer secreting by Calu-3 consists of mucin 
genes 5 (MUC5) and MUC5B which are the major mucins present in human healthy 
airway secretions and chronic disease conditions, respectively46, 48, 49. In addition, 
Furubayashi et al. reported that the paracellular permeability of MDCK could be 
44 
 
underestimated for the nasal delivery model due to the excessive tight cellular 
junctions50. Therefore, Calu-3 cell line has been widely used as a cell culture model for 
nasal drug absorption and was selected for the current study to optimize the SEN 
formulation for nasal delivery of insulin 51-53.  
The objective of this study was 1) to evaluate the cytotoxic and permeation-
enhancing effects of SENs for the nasal delivery of insulin on Calu-3 cells and 2) to 
investigate the stability of the insulin in the selected SEN formulation by Thioflavin T 
assay for the determination of fibril formation.  
2.1 Materials  
Acetic acid (Glacial) and Kolliphor®RH40 was purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Acetonitrile ≥ 99.8% for HPLC, Eagle's Minimum Essential 
Medium (EMEM), Trifluoroacetic acid (TFA) were purchased from VWR (West Chester, 
PA, USA). Captex®8000 (G8T, C8 Triglycerides) and Capmul® MCM (G8/10MD, C8/10 
Mono- and Di-glycerides) were kindly gifted by Abitec Corporation (Janesville, WI, 
USA). Dimethyl sulfoxide (DMSO) and Methanol (≥99.8%) were purchased from VWR 
(West Chester, PA, USA), and 3-(4.5-dimethylthiazol-2-yl)-2.5-
diphenyltetrazoliumbromide (MTT), Hydrochloric acid (1M), and Thioflavin T (ThT) 
were purchased from Thermofisher Acros Organics (Morris Plains, NJ, USA). 
Dulbecco’s Phosphate-Buffer Saline (DPBS), pH 7.0 without calcium/magnesium, and 
penicillin-streptomycin solution were purchased from Hyclone (Logan, UT, USA). Fetal 
Bovine Serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, GA, 
USA). Human insulin and FITC-Insulin (Human) were purchased from Sigma-Aldrich, 
Co. (St. Louis, MO, USA). Human lung cancer cell line (Calu-3) was purchased from 
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ATCC® (Rockville, MD, USA). PECEOL™,
 Maisine®CC, and Labrasol®ALF were kindly 
gifted from Gattefossé (Paramus, NJ, USA). Trypsin (0.25%) with 0.53 mM 
ethylenediaminetetra acetic acid (EDTA) was purchased from Mediatech Inc. (Manassas, 
VA, USA).   
2.2 Methods 
2.2.1 Preparation and Characterization of SENs Containing FAME 
Four FAMEs were used in this experiment including G8/10MD, G18:1M, 
G18:2MD, and PEG8/10MD. The preconcentrate of SEN was prepared by mixing G8T, 
FAME, and Kolliphor®RH40 at 1:1:2 weight ratio and shaken in a MaxQ™ 4000 
Benchtop Orbital Shaker (Thermo Scientific™, USA) for three hours (300 rpm, 37 °C). 
Then, the preconcentrate was diluted with PBS to form SEN-G8/10MD, SEN-G18:1M, 
SEN-G18:2MD and SEN-PEG8/10MD at 0.4-4% (w/v) for cytotoxicity study and 0.8% 
for transport study. The droplet sizes and zeta potential of SENs were measured by a 
Zetasizer®Nano ZS (Malvern Instrument Inc., USA). The FITC-insulin (1 IU/mL) was 
added to the SENs used in the transport study. 
2.2.2 Cell Culture 
The Calu-3 cells were cultured in the T-25 flasks in the culture medium 
(cMedium) containing EMEM (with phenol red), 10% FBS, and 1% penicillin-
streptomycin solution at 37ºC with 5% CO2/95% air. The cells were split by trypsin 
(0.25%) with 0.53 mM EDTA solution and subcultured when reached 90% confluence. 
2.2.3 Cytotoxicity Study  
The Calu-3 cells were seeded to the 96-well plates at the density of 40,000 
cells/well in cMedium (200 µL). The cells were grown for 22-24 hours before the 
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experiment. The cMedium was removed and 200 µL of fresh cMedium, DPBS, or SENs 
(0.4-4% of the preconcentrates in DPBS) were added to each well (n=6) and incubated at 
37oC for two hours. The test formulations were removed, and the cells were washed once 
with cMedium. Then, the MTT solution (200 µL, 2.5 mg/mL in cMedium) was added to 
each well, and the plates were further incubated for two hours. The MTT solution was 
removed and replaced with DMSO (200 µL), and the plates were covered with foil to 
protect from the light exposure. The plates were agitated for five min and the absorbance 
of formazan at 560 nm in each well was analyzed by a spectrophotometer Glomax® 
Discover microplate reader (Promega, USA). The cell viability (%) was calculated based 
on the absorbance and with the cells treated with cMedium as 100% cell viability. The 
half-maximal inhibitory concentration (IC50) was calculated for each SEN by GraphPad 
Prism 8. 
2.2.4 In Vitro Permeation of FITC-insulin in SEN 
The Calu-3 cells in cMedium at the density of 5 x 105 cells/cm2 were seeded on 
the Transwell® insert with a surface area of 0.33 cm2/well and membrane pore size of 0.4 
µm and incubated at 37oC. The culture media was changed every other day. The Calu-3 
monolayer was typically formed on the Transwell® insert after 13-15 days. The TEER 
value was monitored to measure the formation of tight junctions. The monolayers with 
TEER value higher than 500 Ω.cm2 were used in the further experiment 54, 55. The 
confluent monolayers were washed with DPBS once. Then fresh DPBS (1 mL) was 
added to the receiver chamber, and 0.3 mL of the SENs containing FITC-insulin (1 
IU/mL) were added to the donor chamber (n=3), and further incubated for two hours. 
Samples (0.2 mL) were taken at 30, 60, 90, and 120 min from the receiver chamber and 
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replaced with fresh DPBS. The TEER value was measured at the beginning and every 
hour during the transport study.  
The fluorescence intensity of FITC-insulin was analyzed by Glomax® Discover 
microplate reader at excitation/emission wavelength of 475/550-550 nm. The SENs 
containing FITC-insulin added to the donor chamber was diluted 5 times with methanol 
before analyzing for fluorescence and was used as the initial fluorescence. The samples 
from the receiver chamber were analyzed for fluorescence and were used to calculate the 
cumulative transport of FITC-insulin. The cumulative transport of FITC-insulin was 
presented as the percentage of the initial fluorescence. 
2.2.5 Recovery of Monolayer Integrity Pretreated with SENs 
After the 2-h transport study, the monolayers were washed with cMedium twice 
and incubated for 24 hours in cMedium. The TEER value was measured at 1, 2, 4, 6, 12, 
and 24 hours of the recovery period. 
2.2.6 Thioflavin T Assay  
SEN-G8/10MD was used in this study. The SEN-G8/10MD was prepared by 
diluting the preconcentrate with insulin solution in 0.01M HCl (pH 2) or DPBS (pH 7.4) 
to form 1SEN-G8/10MD and 5SEN-G8/10MD (1% and 5% of preconcentrates, 
respectively) containing 2 mg/mL of insulin. The insulin solution in 0.01M HCl was used 
as a positive control for fibril formation. Blank diluent, blank 1SEN-G8/10MD, and 
blank 5SEN-G8/10MD in both 0.01M HCl and DPBS were used as a background 
reading. Table 6 summarizes the tested formulations used in the study. 
Thioflavin (ThT) was dissolved in DPBS and prepared as 1 mM stock solution. 
The stock solution (0.1 mL) was added to each formulation (10 mL, n=3) and incubated 
48 
 
at 60˚C to accelerate the fibril formation of insulin. The sample (20 µL) was taken at 0, 3, 
5, 12, and 24 hours into 96-well plate. The ThT fluorescence was measured immediately 
after the samples were withdrawn by using the SpectraMax microplate reader (Molecular 
Devices, USA) at excitation/emission wavelength of 482/450 nm and 37°C.  
2.2.7 Statistical Analysis 
The data are expressed as mean ± standard deviation (n=6 for cell viability, and 
n=3 for transport study and ThT assay). The viability and transport of FITC-insulin were 
analyzed by one-way ANOVA followed by Tukey’s HSD Post-hoc test. The fluorescence 
intensity in ThT assay was analyzed by paired t-test to compare the difference between 
the fluorescence at the studied time with the corresponding initial fluorescence at time 
zero. The difference was considered significant when p<0.05.  
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Table 6 Details of formulations analyzed by Thioflavin T assay. 
Sample# Formulation Diluent  
1 Blank diluent 0.01M HCl (pH 2) 
2 Blank 1SEN-G8/10MD 0.01M HCl (pH 2) 
3 Blank 5SEN-G8/10MD 0.01M HCl (pH 2) 
4 Insulin solutiona 
(positive control) 
0.01M HCl (pH 2) 
5 Insulin in 1SEN-G8/10MD 0.01M HCl (pH 2) 
6 Insulin in 5SEN-G8/10MD 0.01M HCl (pH 2) 
7 Blank diluent DPBS (pH 7.4) 
8 Blank 1SEN-G8/10MD DPBS (pH 7.4) 
9 Blank 5SEN-G8/10MD DPBS (pH 7.4) 
10 Insulin solution DPBS (pH 7.4) 
11 Insulin in 1SEN-G8/10MD DPBS (pH 7.4) 
12 Insulin in 5SEN-G8/10MD DPBS (pH 7.4) 




2.3 Results and Discussion 
2.3.1 Preparation and Characterization of SENs Containing Selected FAMEs 
The mean droplet sizes of the 0.8% SENs including SEN-G8/10MD, SEN-
G18:1M, SEN-G18:2MD and SEN-PEG8/10MD were 29±4, 36±7, 38±14, 29±8 nm, 
respectively. The mean droplet size of all the SENs was approximately 30-40 nm and 
remained unchanged from 0.4-4%. The zeta potential of the SEN-G8/10MD, SEN-
G18:1M, SEN-G18:2MD and SEN-PEG8/10MD were -4.49±1.14, -2.35±0.74, -
1.32±0.67, and -3.92±0.20 mV, respectively. This indicates that the difference in FAME 
types did not significantly (p>0.05) affect the zeta potential of the SENs. 
2.3.2 Cytotoxicity of SEN Containing Selected FAMEs 
 Figure 8 shows that the reduction in the viability of the cells exposed to SEN-
G8/10MD, SEN-G18:2MD and SEN-PEG8/10MD was concentration-dependent. 
However, no reduction in the cell viability was observed by SEN-G18:1M. The cell 
viability exposed to all the SENs at 0.8% (containing 0.2% of FAMEs) was higher than 
80% indicating non-toxic at this concentration. Therefore, the SENs at 0.8% were 
selected for further transport study. Table 7 shows the calculated IC50 of the SENs. The 
highest IC50 was found with SEN-G18:1M which was higher than SEN-PEG8/10MD, 
SEN-G18:2MD, and SEN-G8/10MD, respectively. These results were correlated to the 





Figure 8 Cytotoxicity of (♦) SEN-G8/10MD; (■) SEN-G18:1M; (▲) SEN-G18:2MD; 
(✕) SEN-PEG8/10MD at various concentrations (mean ± SD, n=6). 
 
Table 7 The half maximal inhibitory concentration (IC50) of SENs containing the 
selected FAMEs. 
SENs IC50 (% v/v) 
SEN-G8/10MD 0.2367 ± 0.0076 
SEN-G18:2MD 0.2805 ±0.0177 




















Concentration of FAME in SEN (% v/v)
52 
 
2.3.3 In Vitro Permeation of FITC-insulin in SEN  
 The cumulative transports of FITC-insulin achieved by PBS, Kolliphor®RH40 
(1%), and SENs (0.8%) were shown in Figure 9. After 2-h transport study, the cumulative 
transport of FITC-insulin achieved by PBS, Kolliphor®RH40 (1%), and SEN-G18:1M 
were similar (0.05±0.01%, 0.17±0.10% and 0.21±0.18, respectively). However, the SEN-
G8/10MD, SEN-G18:2MD, and SEN-PEG8/10MD significantly (p<0.05) increased the 
transport of FITC-insulin to 3.03±0.80%, 0.68±0.27%, 0.61±0.39%, respectively. The 
increasing orders of insulin transport were consistent with the IC50 of FAMEs (low – 
high). The transport of insulin at 30 min achieved by SEN-G8/10MD and SEN-
PEG8/10MD was significantly (p<0.05) higher than PBS, Kolliphor®RH40, and the other 
SENs indicating that the permeation-enhancing effect of these two occurred rapidly. The 
transport of insulin achieved by SEN-G8/10MD was also significantly (p<0.05) higher 
than SEN-PEG8/10MD at any time point showing that SEN-G8/10MD had the highest 
capability as a permeation enhancer of insulin across the cell monolayer.  
2.3.4 Recovery of Monolayer Integrity Pretreated with SENs 
 Figure 10 shows the TEER value of the cell monolayers during the 2-h transport 
study and 24-h recovery. After 2-h transport study, the TEER was reduced by SEN-
G8/10MD, SEN-G18:2MD, and SEN-G18:1M for about 50%, 40%, and 30%, 
respectively, indicating the compromised tight junctions. The reduction in TEER during 
the transport study was correlated to the increase in the transport of insulin by all the 
SENs, except SEN-PEG8/10MD. The TEER was slightly increased by SEN-
PEG8/10MD for about 12%, which may be because PEG8/10MD may involve in cell 
proliferation. The MTT assay (Figure 8) shows that the viability of the cells exposed 
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PEG8/10MD at the concentration ≤ 0.2% was also increased to about 120-130%, 
indicating the increase in mitochondria function which is essential for the cell 
proliferation. The change in TEER value caused by all the SENs reversed to higher than 
90% within 12 hours and fully recovered after 24 hours. The recovery in TEER reduction 
indicates the reversible opening of tight junction by the SEN at the studied concentration 
(0.8%).  



















































Figure 9 Cumulative transport of FITC-insulin across Calu-3 cell monolayer achieved 
by: (♦) PBS; (■) 1% Kolliphor®RH40; (✕) 0.8% SEN-G8/10MD; (●) 0.8% SEN-
G18:1M; (△) 0.8% SEN-G18:2MD; and (○) 0.8% SEN-PEG8/10MD (mean ± SD, n=3). 









































Figure 10 TEER value of the Calu-3 monolayer during and after the 2-h exposure to (♦) 
PBS; (■) 1% Kolliphor®RH40; (✕) 0.8% SEN-G8/10MD; (●) 0.8% SEN-G18:1M; (△) 
0.8% SEN-G18:2MD; and (○) 0.8% SEN-PEG8/10MD (mean ± SD, n=3).   
End of the exposure to SENs 
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2.3.5 Determination of Insulin Stability in Aqueous Phase of SEN by ThT 
Assay  
 ThT is a fluorescence dye which can bind to the amyloid fibrils of proteins or 
peptides. Upon binding between ThT and fibrils, ThT increases the fluorescence intensity 
at 482/450 nm emission/excitation wavelength. Therefore, ThT has been widely used to 
monitor the fibril formation of various proteins including insulin. Two pH conditions 
have been used in the current study including pH 2 and pH 7.4. Insulin solution at pH 2 
usually stays as monomer or dimer which increases the rate of fibril formation, while 
insulin at pH 7.4 favors to form tetramer or hexamer 43. The insulin solution (2 mg/mL, 
pH 2) and the incubation temperature at 60˚C have been proved to be the accelerated 
conditions for insulin to form fibrils 44, 56. Therefore, insulin solution at pH 2 was used as 
a positive control and the formulations were incubated at 60˚C to accelerate the fibril 
formation.  
Figure 11 shows the ThT fluorescence of various test formulations subtracted 
from their corresponding background reading including blank diluent, blank 1SEN-
G8/10MD and blank 5SEN-G8/10MD. The significant (p<0.05) increase in fluorescence 
intensity at 12-h and 24-h incubation at 60˚C was observed with insulin solution (pH 2) 
and insulin in 1SEN-G8/10MD (pH 2) as compared to their initial fluorescence, while 
insulin in 5SEN-G8/10MD (pH 2) showed the similar fluorescence from initial to 24 
hours. When insulin was in the solution or aqueous phase of SEN-G8/10MD at pH 7.4, 
there was no change in fluorescence intensity indicating that there was no fibril formation 
within 24 hours. The result was expected since the insulin at pH 7.4 has been reported to 
exist as dimer or tetramer which are less susceptible to fibril formation. By using the 
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accelerated conditions, the results indicated that SEN-G8/10MD could prevent the fibril 































Figure 11 ThT fluorescence intensity-time profile under accelerated condition indicating 
the fibril formation of insulin (2 mg/mL) in various formulations including (♦) insulin 
solution (pH 2); (■) insulin in 1SEN-G8/10MD (pH 2); (△) insulin in 5SEN-G8/10MD 
(pH 2); (✕) insulin solution (pH 7.4); (●) insulin in 1SEN-G8/10MD (pH 7.4); and (○) 
insulin in 5SEN-G8/10MD (pH 7.4); (mean ± SD, n=3). *: Significantly higher their 








2.3 Trends and Limitations 
As mentioned earlier, SEN has been initially developed to enhance the delivery of 
lipophilic drugs by increasing the solubility of the drug in SEN droplets. The soluble 
form of drug molecules can easily absorb via the transcellular route. Since 2008, our 
laboratory has developed the complex formation technique to increase lipophilicity of 
hydrophilic drugs e.g. beta-lactamase, calcitonin, insulin, etc. Then, the hydrophilic drug 
complex can be loaded into the SEN droplets resulted in the significant increase in the 
relative bioavailability of these hydrophilic drugs, in vivo. Until now, there are many 
research papers applied the similar procedure to load hydrophilic drugs in the SEN 
droplets and have been successfully enhanced the bioavailability of hydrophilic drugs 
through many routes of administration57-59. 
 However, the coadministration of hydrophilic drug in the aqueous phase of SEN 
remains limited, especially for intranasal delivery. Sintov et al., coadministered insulin in 
the aqueous phase of the SEN which was formulated without FAME. It was found that 
the relative bioavailability was less than 1% when administered intranasally. In this 
Chapter, when SEN formulation lacks FAMEs, SEN loses its capability to enhance the 
transport of insulin. This confirms that the permeation enhancement of SEN depends on 
the proper selection of excipients and the main excipient in SEN exhibiting the tight 
junction opening is FAME.  
The limitation in this Chapter is that the concentration of SEN containing FAME 
which was optimized on Calu-3 monolayer for both cytotoxicity and permeation 
enhancement cannot be applied directly toward in vivo concentration. The monolayer 
culture has limitations to reflect the actual nasal epithelium which consists of multiple 
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layers, different morphology, mucociliary clearance, cilia and hairs, etc. Therefore, ex 
vivo evaluation was performed to select the safe and efficient concentration of SEN for in 
vivo study.  
2.4 Conclusion 
SEN-G8/10MD, SEN-G18:2MD, and SEN-PEG8/10MD can significantly 
(p<0.05) enhance the transport of insulin across the Calu-3 monolayer. The SEN-
G8/10MD at non-toxic concentration showed the highest permeation-enhancing effect on 
insulin as compared to the other FAMEs. The SEN-G8/10MD enhance the transport of 
insulin by compromising the tight junctions, but the tight junction integrity was recovered 
after 12 hours. The co-administration of insulin with SEN-G8/10MD can prevent the 
fibril formation of insulin, and the prevention was concentration-dependent. Therefore, 








EX VIVO PERMEATION AND TOXICITY OF INSULIN IN SEN CONTAINING 
G8/10MD 
A literature review shows that G8/10MD has been studied for the nasal delivery 
of some drugs. The highest concentrations of G8/10MD reportedly used in nanoemulsion 
were 15% for the in vivo study in rats and 20% for the ex vivo study on the excised nasal 
mucosa from either goat or sheep 60, 61. The nasal epithelium reported by these 
publications was found the be intact after exposure to such a high concentration of 
G8/10MD. However, as seen in the in vitro studies on Calu-3 cells, SEN containing 
G8/10MD exhibited concentration-dependent toxicity. But the SEN containing G8/10MD 
(0.8%) can significantly (p<0.05) enhance the permeability of insulin without noticeable 
cytotoxicity or the irreversible opening of the tight junctions. In this Chapter, ex vivo 
method was used to further evaluate SEN containing G8/10MD for its toxicity and 
permeation enhancing effect on the bovine nasal mucosa.  
The nasal mucosa from various animals including bovine, porcine, caprine, and 
ovine have been used for ex vivo permeation study across nasal route 11. Among these 
animals, bovine nasal mucosa has been widely used due to the similarity to humans in 
terms of the epithelial types, aminopeptidase activity which is necessary for the stability 
of the therapeutic peptides delivered intranasally, and the presence of both transcellular 
and paracellular transports in the excised mucosa 62, 63. Therefore, bovine nasal mucosa 
was selected as an ex vivo model in the current study. 
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The objective of this chapter was to select the proper concentration of SEN 
containing G8/10MD for the further in vivo study by investigating the permeation-
enhancing effect and nasal ciliotoxicity of the SEN on insulin. 
3.1 Materials 
Ammonium hydroxide solution and human insulin (27.5 IU/mg) were purchased 
from Sigma-Aldrich, Co. (St. Louis, MO, USA). Acetic acid (Glacial) and 
Kolliphor®RH40 was purchased from Millipore Sigma (St. Louis, MO, USA). 
Acetonitrile ≥ 99.8% for HPLC, Ethanol (100%, reagent grade for histology), Eosin Y 
solution (1%), Haematoxylin solution Gill II, methanol ≥99.8% for HPLC, Isopropyl 
alcohol (IPA), Phloxine B solution (1%), Roswell Park Memorial Institute (RPMI)-1640, 
Trifluoroacetic acid (TFA), Xylene, and Permount™ Mounting Medium were purchased 
from VWR (West Chester, PA, USA). Bovine nasal mucosa was purchased from 
Lampire Biological Inc. (Everett, PA, USA). Captex®8000 (G8T, C8 Triglycerides) and 
Capmul® MCM (G8/10MD, C8/10 Mono- and Diglycerides) were kindly gifted by 
Abitec Corporation (Janesville, WI, USA). Dulbecco’s Phosphate-Buffer Saline, pH 7.0 
with calcium/magnesium was purchased from Hyclone (Logan, UT, USA). Human 
Insulin ELISA Kit was purchased from Crystal Chem (Elk Grove Village, IL, USA).  
3.2 Methods 
3.2.1 Preparation and Characterization of Insulin in SEN   
The preconcentrate of SEN was prepared by mixing G8T, G8/10MD, and 
Kolliphor®RH40 at 1:1:2 weight ratio and being shaken in a MaxQ™ 4000 Benchtop 
Orbital Shaker (Thermo Scientific™, USA) for three hours (300 rpm, 37 °C). The insulin 
stock solution (1 mg/mL in PBS) was prepared. Then, the preconcentrate was diluted 
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with the insulin solution to form 30SEN, 20SEN, and 10SEN (containing 30%, 20%, and 
10% (w/v) of preconcentrate, respectively) with the same concentration of insulin at 10 
IU/mL. 
The droplet sizes and Zeta potential of SENs were measured by a Zetasizer® 
Nano ZS (Malvern Instrument Inc., USA). SENs containing insulin were diluted with 
methanol and the insulin content was quantified by using HPLC (n=3). The concentration 
of insulin in each SEN was used as the initial concentration to calculate the percentage 
transport of insulin in the permeation study. 
3.2.2 HPLC Assay 
The HPLC assay of insulin was carried out on an Agilent 1260 series UV detector 
with C18, 5 μm, 4.6 X 150 mm as the stationary phase. An isocratic method was used, 
and the experiment was run at room temperature. The mobile phase, consisting of 70% 
(v/v) deionized (DI) water, 30% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid 
(TFA), was pumped at flow rate of 1 mL/min over 10 min. The injection volume was 20 
μL and analyzed at a wavelength of 214 nm. The retention time was at 3.6 min and the 
peak area was used to quantify the insulin.  
3.2.3 Preparation of Nasal Mucosa  
Bovine nasal tissues from both the posterior and anterior regions (Figure 12) were 
obtained from freshly-slaughtered bovine. The tissues were stripped from the lateral 
cartilage and transported to the laboratory in ice-cold RPMI-1640. The mucosal tissues 
were carefully cut and excised from the submucosa layer with a scalpel. The mucosal 
specimen with a thickness of 300 µm (measured by Vernier caliper) and the surface area 
of 3.53 cm2 (1.5 cm diameter) was used for the permeation study.  
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3.2.4 Ex vivo Permeation Study 
The Franz diffusion chambers (Figure 13) used in the study had an effective 
diffusion area of 1.27 cm2 (0.9 cm diameter) and a receptor volume of 5.0 ± 0.2 mL. The 
diffusion cells were preincubated at 37 ˚C for 15 min by using the Corio CD-BC4, a 
constant circulation water bath (Julabo, USA). PBS (five mL, at 37 ˚C) was added to the 
receptor chambers and continued stirring using a magnetic bar. The excised mucosa was 
rinsed once with PBS and immediately mounted on the diffusion cells with the mucosal 
surface facing the donor chamber. PBS (one mL, at 37 ˚C) was added in the donor 
chamber and stabilized for 10 min. Then, the PBS was gently removed and the test 
formulations (one mL, at 37 ˚C) were placed. The temperature was controlled at 37±1˚C. 
The samples (200 µL) were taken from the receptor chamber at 30, 60, 90, 120 min and 
replaced with fresh PBS. The samples were diluted with DI water for 200 times and 
analyzed with an Enzyme-linked immunosorbent assay (ELISA). Fresh DI water was 
analyzed for background reading. Insulin solution in PBS (10 IU/mL) was used as the 
control. The permeation of insulin was calculated as the percentage of the initial 










Figure 12 Locations of the collected tissues: (1) Posterior region; (2) Anterior region 








Figure 13 Schematic representation of the Franz diffusion cell used in the ex vivo 
permeation study across bovine nasal mucosa, and the exposed area on the nasal mucosa 

















3.2.5 ELISA Assay Procedure  
In each well, HRP labeled antibody solution (100 µL) was added followed by 
samples (25 µL) and mixed well by repeated pipetting. The microplate was covered with 
the plate sealer and incubated for two hours at 37 ˚C. After incubation, the solution in 
each well was removed and washed with wash buffer (300 µL) for four times. In each 
wash, any remaining solution in the well was removed by inverting and tapping the plate 
firmly on a clean paper towel. The plate was then kept in the darkroom to protect from 
light. The substrate solution (100 µL) was added to each well and incubated in dark for 
15 min at room temperature. The stop solution (100 µL) was added to stop the reaction 
and the absorbance at 450 nm was immediately analyzed by a spectrophotometer 
Glomax® Discover microplate reader (Promega, USA). The concentration of insulin in 
samples was calculated according to the standard curve. 
3.2.6 Nasal Ciliotoxicity Study 
3.2.6.1 Formalin Fixation and Paraffin Embedding 
 The exposed area (Figure 13) of the mucosa after 2-h treatment with the 
formulations were cut and fixed in 10% formalin for 24 hours. The fixed tissues were 
trimmed into appropriate size and dehydrated according to the procedure in Table 8. The 
dehydrated tissues were embedded in paraffin. Thin sections (7 µm) of tissue were 
prepared by a microtome. The mucosa treated with insulin solution in phosphate buffer 
saline (PBS) and 20% Isopropyl alcohol (IPA) were considered as the negative and 




Table 8 Tissue dehydration and infiltration procedure. 
Step Solutions Submerging time (h) 
1 Ethanol (70%) 2 
2 Ethanol (80%) 2 
3 Ethanol (90%) 2 
4 Ethanol (100%) 2 
5 Ethanol (100%) 2 
6 Ethanol (100%)) 2 
7 Xylene 2 
8 Xylene 2 
9 Paraffin (melted at 60˚C) 1 






3.2.6.2 Hematoxylin and Eosin (H&E) Staining 
The Eosin-Phloxine solution was prepared by mixing 11% Eosin solution, 1.5% 
Phloxine B solution, 87% Ethanol (95%), and 0.5% Glacial Acetic acid. The thin sections 
were mounted on the glass slide and stained in hematoxylin and eosin solutions following 
the solutions and time described in Table 9. The stained sections were observed and 
photographed by Nikon Eclipse Ts2R microscope with Nikon DS-Qi2 camera.  
3.2.7 Data Analysis 
The data are expressed as mean ± standard deviation (n=3). The transport of 
insulin was analyzed by student’s t-test to compare the difference between SENs and 




Table 9 Hematoxylin and Eosin (H&E) staining procedure. 
Step Solutions Submerging time 
(min) 
1 Xylene 5 
2 Xylene 5 
3 Xylene 5 
4 Ethanol (100%) 2 
5 Ethanol (95%) 2 
6 Ethanol (70%) 2 
7 Ethanol (30%) 2 
8 Distilled water  1 
9 Haematoxylin solution Gill II 10 
10 Distilled water 1 
11 Tap water 1 
12 Ethanol (70%) and Ammonium hydroxide (1%) 1 
13 Tap water 1 
14 Distilled water 2 
15 Ethanol (70%) 2 
16 Eosin-Phloxine solution 2 
17 Ethanol (95%) 2 
18 Ethanol (100%) 2 
19 Ethanol (100%) 2 
20 Ethanol (100%) 2 
21 Xylene 2 
22 Xylene 2 






3.3 Results and Discussion 
3.3.1 Preparation and Characterization of Insulin in SEN   
Table 10 shows the mean droplet size and zeta potential of the blank SENs at 
different dilutions. The mean droplet size and zeta potential of the SENs were 
approximately 30 nm and -2 mV, respectively, indicating the concentration of 
preconcentrate in the SEN did not change the zeta potential and droplet sizes. The insulin 
content added in the SENs analyzed by HPLC was 9.2-9.9 IU/mL. 
3.3.2 Ex vivo Permeation and Nasal Ciliotoxicity Studies 
Figure 12 shows the locations of bovine nasal tissues that were collected to 
perform the studies. Two regions included the anterior tissue (approximately 3-inch depth 
from the external opening) and the posterior tissue located in the nasal cavity.  
Figure 14 demonstrates the difference between the mucosa collected from the 
anterior and posterior regions. The epithelial layer of the anterior tissue was 
approximately 3-fold thicker than the posterior tissue.  
The delivery of liquid formulation through the nasal route has been achieved by 
using the liquid nasal spray. The currently available liquid spray devices include 
traditional liquid spray device and Bi-directionalTM delivery device. Djupesland et al. 
explained that the traditional liquid spray provides the greatest deposition in the lower 
anterior region of the nasal cavity, whereas the deposition provided by the bi-
directionalTM liquid delivery device was greatest in the upper posterior region of the nasal 
cavity (Figure 15) 64.  
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Detailed examination of the human nasal epithelium shows that the anterior and 
posterior regions of the nasal cavity are lined with the different epithelial types and 
exhibited unequal thickness. One-third of the human epithelium consists of stratified 
squamous epithelium located in the anterior region (nasal vestibule and atrium). The 
posterior of the nasal cavity covering two-third of the epithelium is called respiratory 
region lining with pseudostratified columnar ciliated epithelium which is a single layer of 
cells appearing to be stratified. The permeability of the drug was highest across the 
respiratory region > atrium > nasal vestibule 65. However, in literature, the differences in 
epithelium types and thickness between these two regions have been somehow neglected 
during the determination of toxicity and permeation-enhancing effect of the formulation. 















30SEN 7.5% 32 ± 9 0.068 ± 0.021 -1.58 ± 0.86 
20SEN 5% 30 ± 7 0.055 ± 0.013 -2.50 ± 0.77 



















Figure 14 The differences of nasal mucosa between anterior and posterior regions. (A) 
Anterior (stratified squamous epithelial cells); (B) Posterior (pseudostratified ciliated 


































Figure 15 Schematic of the sagittal section of the nasal cavity. Top: different sections of 
the nasal cavity: (A) nasal vestibule; (B) atrium; (C) respiratory region; (D) olfactory 
region; and (E) nasopharynx, reported by Djupesland et al. 64. Bottom: Gamma camera 
image information (logarithmic “hot iron” intensity scale) from the nasal cavity is 
superimposed on the corresponding sagittal MRI section. The images are from the same 
object and present deposition 2 min after delivery using (Left) a traditional liquid spray, 





3.3.2.1 Posterior Region 
Figure 16A shows the cumulative transport of insulin across the posterior mucosa. 
The 2-h cumulative transport of insulin in 30SEN and 20SEN were significantly (p<0.05) 
higher than insulin in PBS (0.74 ± 0.21% and 0.37 ± 0.01% vs 0.15 ± 0.01%), whereas 
insulin in 10SEN showed the similar transport as compared to insulin solution (0.18 ± 
0.03% vs 0.15 ± 0.01%). These indicate that the permeation-enhancing effect of SEN 
containing G8/10MD was concentration-dependent which was expected from the in vitro 
permeation study in Chapter 2. However, the concentration of the preconcentrate in SEN 
which can significantly (p<0.05) increase the transport of insulin was 20% (containing 
5% G8/10MD) which was 25-fold higher than the concentration used in the in vitro 
studies (0.8% SEN containing 0.2% G8/10MD).  
The microscopic images of posterior mucosa pretreated with insulin solution 
(negative control), insulin in SENs, and 20% IPA (positive control) were shown in Figure 
17-18. The intact pseudostratified columnar epithelium was observed in the mucosa 
pretreated with 10SEN and insulin solution (Figure 17A-B). The epithelium pretreated 
with 20SEN (Figure 17C) was observed to be thinner as compared to the negative 
control, but the layer of epithelium remained observable. The epithelium pretreated with 
30SEN was found to be damaged (Figure 17D) indicating higher toxicity than 20SEN, 
but no inflammatory cells were observed. The epithelium pretreated with the positive 
control exhibited an increase in inflammatory cells with the damaged epithelium (Figure 
18). The nasal ciliotoxicity of SEN containing G8/10MD was also concentration-
dependent which was correlated to the in vitro cytotoxicity in Chapter 2.   
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3.3.2.2 Anterior Region 
Although 30SEN exhibited the highest permeation-enhancing effect on insulin 
across posterior mucosa, this concentration caused damage to the posterior epithelium. 
Therefore, the highest concentration used in the anterior mucosa was 20SEN. The 2-h 
cumulative transport of insulin achieved by 20SEN was significantly (p<0.05) increased 
from insulin solution (0.45 ± 0.12% vs 0.12 ± 0.01%). The 2-h cumulative transport of 
insulin from insulin in 20SEN, 10SEN, and solution across the anterior mucosa (Figure 
16B) were similar to the posterior mucosa (p > 0.05). However, at 90 min, the transport 
of insulin across anterior mucosa was significantly (p<0.05) lower than the transport 
across posterior mucosa (0.15 ± 0.04% vs 0.30 ± 0.06%) (Figure 16), indicating the delay 
in permeation enhancement of SEN. This may be due to the thicker layer of the 
epithelium in the anterior region making it more difficult for SEN to enhance the 
transport of insulin.   
 Figure 19 shows the nasal ciliotoxicity of the mucosa. The intact epithelium was 
also observed with the mucosa pretreated with 10SEN and insulin solution as similar to 
the posterior region. However, the increase in inflammatory cells was observed in the 






























































































Figure 16 Cumulative transport of insulin across bovine nasal mucosa located in (A) 
posterior region; (B) anterior region, following ■) insulin solution; (△) i.n. insulin in 
10SEN; (▲) i.n. insulin in 20SEN; (✕) i.n. insulin in 30SEN (mean ± SEM; n=3). *: 















Figure 17 Nasal mucosa from the posterior region exposed to insulin loaded in (A) 
phosphate buffer saline (negative control); (B) 10SEN (containing 2.5% G8/10MD); (C) 
























Figure 18 Nasal mucosa from the posterior region exposed to 20% IPA (positive 




























Figure 19 Nasal mucosa from the anterior region exposed to insulin loaded in (A) 
phosphate buffer saline; (B) 10SEN (containing 2.5% G8/10MD); (C) 20SEN (containing 
5% G8/10MD). Scale bar is 100 µm. Yellow arrows indicate inflammatory cells.  
(B) (A) (C) 
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3.4 Trends and Limitations 
Bovine nasal mucosa has been reported for its similarity to human nasal 
epithelium. However, the limitation of the excised nasal mucosa is the thickness. Human 
nasal epithelium has the thickness of 50 µm, but the thinnest bovine nasal mucosa which 
can be prepared is approximately 300 µm. It was observed that the thinner layer (< 300 
µm) caused the leakage of formulation from donor to receiver chamber of Franz diffusion 
cell. Therefore, the nasal mucosa used in this Chapter included both epithelium and 
subepithelial layers which caused the insulin detected in the receiver chamber did not 
represent the actual absorption of insulin in the blood circulation. Once the insulin 
transported across the epithelium, the insulin molecule should be absorbed to the blood 
circulation through the abundant vascular networks presented in the subepithelial layers, 
rather than transport across these layers to the receiver chamber. As the result, even 
though the transport of insulin was significantly (p < 0.05) increased only by 20SEN, the 
lower concentration of SEN may be effective in the in vivo study. 
In addition to the permeation result, the nasal ciliotoxicity determined from 
histological study can only represent the toxicity of the epithelial layer. The effect on 
cilia cannot be concluded because there is no cilia observed in any samples including the 
untreated epithelium which may due to the processing time from when animals are 
slaughtered to the experiment.  
3.5 Conclusion  
The 2-h transport of insulin across the nasal mucosa from both anterior and 
posterior regions was significantly (p<0.05) enhanced by 20SEN, while 10SEN did not 
enhance the transport of insulin. After 2-h treatment, the 20SEN caused minimum 
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nasociliotoxicity on the bovine nasal mucosa, while no toxicity was observed with the 





IN VIVO PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF 
INSULIN IN SEN CONTAINING G8/10MD ON STREPTOZOTOCIN-INDUCED 
DIABETIC RATS 
  Various animal models have been used for the in vivo study for the nasal delivery 
of insulin. As shown in Table 11, there are differences between interspecies including 
body weight, nasal volume, nasal surface areas, and epithelium types. However, due to 
the easy accessibility and suitability for the early-stage experiment, rats have been widely 
used by more than 50% of the publications as the first mammalian species for the nasal 
delivery system. Two types of epithelium are lining in the nasal cavity of rats. The nasal 
septum is covered by ciliated pseudostratified columnar epithelium and the nasoturbinate 
is covered with ciliated pseudostratified cuboidal epithelium. The tight junctions are 
presented throughout the nasal cavity 66. It can be seen that the rat’s nasal cavity is a good 
representation of the posterior region of the human nasal cavity due to the similarity in 
the epithelial type 65.      
Diabetic induction in rats has been widely used as a model for diabetic treatment. 
The study on diabetic rats helps to predict the therapeutic efficacy of the formulation in 
the disease conditions e.g. blood glucose level, malfunction of the pancreas, etc. which 
better represent diabetic patients. Various types of diabetic induction have also been 
reported in the literature including spontaneous autoimmune, genetically induced, virally 
induced, and chemical induction including Alloxan and Streptozotocin (STZ), etc. 67. 
STZ has a similar structure to glucose which can enter the pancreatic beta-cell through 
Glut-2 transporter and consequently inhibits insulin production to induce type I diabetes 
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67, 68. Many publications indicate that the high dose STZ injection (0.2 mmol/kg body 
weight) is the simplest model with the high success rate and low implications to induce 
diabetes which is suitable for testing the new formulations of insulin 69-72. Therefore, the 
high dose STZ injection was selected as the method to induce diabetes in this study.  
The objective of the current chapter is to investigate the effect of SEN 
concentration on the intranasal absorption of insulin by using STZ-induced diabetic rats 
as an animal model. The highest concentration of SEN used in this study was 20SEN 






















Man 70 15-20 160 0.1-0.3 Stratified squamous epithelium;  
Ciliated pseudostratified 
columnar epithelium 
Monkey 7 8 62 0.1-0.3 Stratified squamous epithelium;  
Ciliated pseudostratified 
columnar epithelium 
Dog 10 20 221 0.1-0.3 Stratified squamous epithelium;  
Ciliated pseudostratified 
columnar epithelium 
Sheep 40-60 114 327 0.3-0.6 Stratified squamous epithelium;  
Ciliated pseudostratified 
columnar epithelium 
Rabbit 2-4 6 61 0.1-0.25 Stratified squamous epithelium;  
Ciliated pseudostratified 
columnar epithelium 
Rat 0.25 0.4 14 0.02-0.1 Ciliated pseudostratified 
columnar epithelium;  
Ciliated pseudostratified 
cuboidal epithelium 
Mouse 0.03 0.03 2.8 N/A N/A 




Captex®8000 (G8T, C8 Triglycerides) and Capmul® MCM (G8/10MD, C8/10 
Mono- and Diglycerides) were kindly gifted by Abitec Corporation (Janesville, WI, 
USA). Citrate buffer solution (0.5 M, pH 4.5), Sodium lauryl sulfate, Formalin (10%), 
Acetonitrile ≥ 99.8% for HPLC, Ethanol (100%, reagent grade for histology), Eosin Y 
solution (1%), Haematoxylin solution Gill II, methanol ≥99.8% for HPLC, Isopropyl 
alcohol (IPA), Phloxine B solution (1%), Trifluoroacetic acid (TFA), Xylene, and 
Permount™ Mounting Medium were purchased from VWR (West Chester, PA, USA). 
Dulbecco’s Phosphate-Buffer Saline, pH 7.0 with calcium/magnesium was purchased 
from Hyclone (Logan, UT, USA). Ammonium hydroxide solution and Human insulin 
(27.5 IU/mg) was purchased from Sigma-Aldrich, Co. (St. Louis, MO, USA). Human 
Insulin ELISA Kit was purchased from Crystal Chem (Elk Grove Village, IL, USA). 
Isoflurane was purchased from Covetrus (Portland, ME, USA). Acetic acid (Glacial) and 
Kolliphor®RH40 was purchased from Millipore Sigma (St. Louis, MO, USA). 
Streptozotocin was purchased from Adipogen®Life Sciences (San Diego, CA, USA). 
RDO rapid decalcifier was purchased from Apex Engineering products corporationTM 
(Aurora, IL, USA). 
4.2 Methods 
4.2.1 Preparation of SEN Formulations  
The preconcentrate of SEN consisted of G8T, G8/10MD, and Kolliphor®RH40 at 
1:1:2 weight ratio. This preconcentrate was diluted 5, 10, and 20-time with phosphate 
buffer saline (PBS) to make 20SEN, 10SEN, and 5SEN (containing 20%, 10% and 5% of 
87 
 
the preconcentrate respectively). Insulin was added into the aqueous phase of SENs at the 
concentration that can provide 3 IU/kg at 50-µL dose volume.  
4.2.2 Induction of Diabetes in Rats  
The male Sprague Dawley rats (200-250 g) were fasted with water ad libitum for 
12 hours before the diabetic induction. Streptozotocin (STZ) solution in 10 mM ice-cold 
citrate buffer at pH 4.5 was freshly prepared and covered with foil to protect from light. 
The fasted rats were given a single intraperitoneal (i.p.) injection of this STZ solution at 
0.2 mmol/kg body weight. After injection, all the rats were allowed to stabilize with free 
access to food and water ad libitum. The fed blood glucose was measured 48 hours after 
STZ injection by using AimStrip® Plus Blood Glucose Meter (Germaine Laboratories, 
TX, USA) to determine the diabetic condition. Only the rats with blood glucose levels 
higher than 300 mg/dL are considered diabetic and were used in the study.  
4.2.3 Administration of Formulation in Diabetic Rats 
Streptozotocin-induced diabetic rats (250-300 g) were randomly divided into 
seven groups (n=3-4) and administered with the formulations according to Table 12. 
Group I was received insulin solution in PBS (1 IU/kg) by subcutaneous (s.c.) injection 
which was used as the control group for the evaluation of bioavailability (BA) and 
pharmacodynamic availability (PA) of the intranasal (i.n.) groups. Groups II-IV were 
intranasally administered with the test formulations including insulin in 20SEN, 10SEN, 
and 5SEN, respectively. Group V was received i.n. administration of insulin solution 
containing sodium lauryl sulfate (SLS) which was used as the positive control for nasal 
toxicity. Groups VI and VII were received insulin solution and phosphate buffer saline 
(PBS), respectively, by the i.n. administration, and were used as the negative controls.  
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The rats were fasted with water ad libitum for 12 hours prior to the experiment. 
The fasted rats were anesthetized by 3% isoflurane for a few mins and kept under 2% 
isoflurane for 20-30 min to stabilize the blood glucose level. The stabilized glucose level 
was used as initial blood glucose (100%). Then, the treatment was given. The nasal 
administration was done on the right nasal cavity using a micro-syringe connected to gel-
loading tips. Then, 1.5% isoflurane was used to maintain the unconscious effect for 4 
hours. 
After the administration of the formulation, blood samples (200 µL) were 
collected by tail tipping at 5, 15, 30, 45, 60, 90, 120, 180, and 240 min into heparin-
coated microcentrifuge tubes. The blood glucose level was also measured using the 
glucose meter at 5, 10, 15, 30, 45, 60, 90, 120, 180, and 240 min. After the final sampling 
at 240 min, the animals were euthanized by carbon dioxide inhalation. The head was 
collected for histological study to evaluate the toxicity of the formulation. The blood 
samples were centrifuged at 10,000 g for 5 min. The plasma was separated and stored at -
20˚C until further analysis. The plasma concentration of insulin was determined by 
Human-insulin ELISA kits (Crystal Chem, IL, USA) following the method explained in 
Chapter 3.  
4.2.4 Pharmacokinetic and Pharmacodynamic Analysis 
Standard non-compartmental analysis was performed on Pheonix Winnolin 8.2 
(Certara USA, Inc., NJ, USA) for the determination of the pharmacokinetic and 
pharmacodynamic parameters. The area above the curve (AAC) of the intranasal groups 
(Group II-VI) was calculated by using the blood glucose level from the intranasal 
administration of PBS (Group VII) as a baseline.  
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With S.C. group as the reference, the relative pharmacological availability (PA) 
and relative bioavailability (BA) of the intranasally administered insulin were calculated.  




 × 100, 
where, AACf is the area above the curve of glucose reduction-time curve of formulation or 
buffer group; AACs.c. is the area above the curve of glucose reduction-time curve of 
subcutaneous injection group, Dosei.n. is the intranasal delivery dose (3 IU/kg) and Doses.c. is 
the subcutaneous delivery dose (1 IU/kg). 




 × 100, 
where, AUCf is the area under the insulin-time curve of formulation or buffer group; AUCs.c. 
is the area under the curve of the insulin-time curve of subcutaneous injection group, Dosei.n. 
is the intranasal delivery dose (3 IU/kg) and Doses.c. is the subcutaneous delivery dose (1 
IU/kg). 
4.2.5 Histological Study 
 The treated rats were decapitated, and the specimens were fixed in formalin 
solution (10%). After fixation, the skin of the specimens was removed prior to the 
decalcification. The specimens were decalcified with RDO rapid decalcifier containing 5-
9% hydrochloric acid for 4 hours. The nasal cavity from section II was excised and 
briefly rinsed with DI water66. The excised cavity was kept in formalin solution for 
another 24 hours. Then, the nasal cavity was undergone dehydration and paraffin 
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embedding according to the procedure described in Section 4.2.7.1. Thin sections (7 µm) 
of tissue were cut by using a microtome and stained with H&E solutions as described in 
Section 4.2.7.2. The stained sections were observed and photographed by Nikon Eclipse 
Ts2R microscope with Nikon DS-Qi2 camera. 
4.2.6 Statistical Analysis 
The values were expressed as mean ± standard error of the mean (SEM). 
Statistical analysis was performed by One-way ANOVA followed by Tukey’s HSD Post-












I Insulin solution  Subcutaneous 1 IU/Kg 500 µL 
II Insulin in 20% SEN 
(20SEN) 
Intranasal 3 IU/Kg 50 µL 
III Insulin in 10% SEN 
(10SEN) 
Intranasal 3 IU/Kg 50 µL 
IV Insulin in 5% SEN 
(5SEN) 
Intranasal 3 IU/Kg 50 µL 
V 1% Sodium lauryl sulfate Intranasal 3 IU/Kg 50 µL 
VI Insulin solution Intranasal 3 IU/Kg 50 µL 






4.3 Results & Discussion 
4.3.1 Pharmacodynamic Analysis  
The blood glucose level of the rats before the experiment were shown in Table 13. 
After 48 hours of STZ injection, all the rats became diabetes with the average blood 
glucose level of 368.40 ± 14.42 mg/dL. The diabetic condition in rats was maintained 
until the day of the experiment.  
The hypoglycemic effect from various concentrations of SENs was shown in 
Figure 20. The average stabilized blood glucose before dosing was 228.16 ± 16.47 mg/dL 
and was used as the initial blood glucose (Table 13). The i.n. administration of insulin in 
20SEN, 10SEN, and 5SEN significantly (p<0.05) reduced blood glucose levels in 
diabetic rats as compared to insulin solution. The maximum reduction in blood glucose 
level was observed at 90 min after dosing. The highest blood glucose reduction was 
achieved by 20SEN followed by 10SEN and 5SEN, resulted in the blood glucose level of 
55.39±2.54%, 73.89±2.79%, and 79.83±8.64% of initial blood glucose, respectively. The 
hypoglycemic effect lasted until 240 min from 20SEN and 10SEN, and until 120 min 
from 5SEN.  
Table 14 shows the relative PA as compared to s.c. injection of insulin solution (1 
IU/kg). The relative PA achieved by 20SEN, 10SEN, and 5SEN were 79.3 ± 9.4%, 58.4 
± 7.7%, and 42 ± 13.0%, respectively, which were significantly (p<0.05) higher than the 
solution form (1.4 ± 6.1%). The relative PA by 20SEN was also significantly (p<0.05) 
higher than the SLS solution (33.9 ± 8.9%). 
The maximum blood glucose reduction achieved by insulin in SLS solution was 
observed at 45 min and resulted in the blood glucose level of 54.66±2.87% of the initial 
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blood glucose, which was similar to the maximum glucose reduction achieved by 20SEN. 
However, after 45 min, the glucose level bounced back at a much faster rate as compared 
to insulin in the SENs. SLS has been known to cause severe damage to the nasal mucosa 
80. Therefore, the glucose reduction at the beginning of the study could be the result of the 
high amount of insulin rapidly absorbed across those severely damaged nasal mucosae.  
The rats which were intranasally administered with insulin solution or blank PBS 
showed the significant (p<0.05) increase in blood glucose level which continuously 
increased to about 160% at the end of the experiment (240 min). These indicate that the 
administration of the liquid formulation into the nasal cavity could trigger the increase in 
blood glucose level which was correlated with several publications 81-85. Based on these 
results, the increase in blood glucose by i.n. PBS was taken into consideration when the 
AAC for PA evaluation was calculated for the other intranasal groups.  
To confirm the effect of isoflurane on blood glucose level, the other three rats 
were tested with isoflurane (1.5%) alone, without intranasal administration of liquid, for 
four hours. The result showed that there was a slight reduction in blood glucose level at 
90 min, resulting in the blood glucose level of 85.52 ± 0.42% of initial blood glucose. 
And after 90 min, the blood glucose level returned to about 100% and stable until the end 
of the experiment. Nishino et al. reported that the use of isoflurane at low concentration 
(1-3%) did not produce any reflex responses from respiratory, laryngeal, and tracheal as 
well as no change in tracheal smooth muscle tone86. This indicates that the use of 1.5% 
isoflurane had a minimum effect on the blood glucose level and drug absorption across 




Table 13 Blood glucose level of the rats before the experiment (mean ± SEM, n = 25). 
Conditions Blood Glucose 
Level (mg/dL) 
After 48-hour of STZ injection with free access to food and water  368.40 ± 14.42 
The day before the experiment with free access to food and water 363.04 ± 8.67  
After fasting for 12-14 hours with free access to water 185.92 ± 13.55  
After fasting for 12-14 hours and then anesthetized by 3% 
isoflurane and stabilized for 20-30 min with 2% isoflurane (Initial 
blood glucose) 





4.3.2 Pharmacokinetic Analysis 
Figure 21 exhibits the plasma insulin-time profiles following various 
formulations. The 20SEN, 10SEN, and 5SEN resulted in the highest plasma insulin 
concentration (Cmax) of 247.2±12.2, 101.3±8.0, and 53.2±17.6 µU/mL, respectively, 
which were significantly (p<0.05) higher than the solution form (13.5±6.7 µU/mL). The 
Cmax by 20SEN and 10SEN were also significantly (p<0.05) higher than the Cmax by the 
s.c. injection (68.5±31.3 IU/mL). The Tmax of insulin in 5SEN was found at 5 min, 
while Tmax of insulin in 10SEN and 20SEN was approximately 8 and 12 min, respectively 
(Table 14). 
Table 14 also shows the relative BA as compared to s.c. injection of insulin 
solution (1 IU/kg). The 20SEN, 10SEN and 5SEN achieved 37.9±7.6%, 19.3±5.4%, and 
8.8±6.4% relative bioavailability (BA) as compared to the s.c. injection, which were 8.5-, 
3.8-, and 1.2-fold higher than that by the solution, respectively. The relative BA of i.n. 
insulin in 20SEN was also significantly higher (p<0.05) than insulin in 5SEN. The insulin 
in SLS resulted in a relative BA of 24.1 ± 3.6% which was between those by the 20SEN 
and 10SEN. 
The SENs containing G8/10MD exhibited the capability to enhance insulin 
absorption across the nasal route resulted in the significantly increased relative PA and 
relative BA. The permeation enhancing effect of SEN containing G8/10MD was found to 
be concentration-dependent. The 20SEN which was the highest concentration in the study 
showed the highest relative PA and relative BA among all the formulations. 
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4.3.3 Histological Study 
 Figure 22-24 show the vertical cross-sections of the rat nasal cavities including 
the nasal septum which connects two-side nasal cavities, olfactory epithelium, and 
respiratory epithelium. The nasal epithelial throughout the cavity exposed to HI solution, 
10SEN and 20SEN were intact (Figure 22A-C). There was no compromise in the 
integrity of olfactory epithelium and respiratory epithelium observed on both sides of the 
cavity as shown in Figure 23A-C and Figure 24A-C, respectively. It can be concluded 
that there was no noticeable nasal ciliotoxicity caused by the SEN containing G8/10MD 
from the studied concentrations.  
Figure 22D indicates the ciliotoxicity caused by SLS, positive control. Both 
olfactory and respiratory epithelial on the right cavity (treated side) were severely 
damaged by SLS solution, whereas the epithelium on the left cavity was intact until the 
respiratory epithelium near the dorsal nasal meatus which was also damaged (Figure 23D 
and Figure 24D). This may be due to the distribution of the solution into the untreated 
side.  
4.4 Trends and Limitations 
 The results from the present study showed that i.n. insulin in 10SEN (90% of 
PBS) and 20SEN (80% of PBS) had the relative BA of 19.3 ± 5.4% and 37.9 ± 7.6% 
which were 5-fold and 9.5-fold higher than i.n. insulin solution, respectively. With the 
solubility of insulin in PBS (55 IU/mL), Human insulin can be loaded in 10SEN and 
20SEN upto 49.5 and 44 IU/mL, respectively. To achieve the 50 IU dose for a male 
patient (75 kg), approximately 1 mL of the formulation is required (0.25 mL per puff, and 
4 puffs per dosing). This indicates that both 10SEN and 20SEN are applicable to apply in 
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human. However, the current study only shows that a single dose of SEN does not cause 
any noticeable toxicity. Therefore, the long-term toxicity of the formulated SEN cannot 
be concluded and will require further study.  
Sintov et al. reported that the i.n. insulin in w/o SEN improved the relative BA of 
21.5% in diabetic rabbits, while o/w SEN did not improve BA of insulin. The w/o SEN 
contained 20% of aqueous and 80% of lipid phase including surfactants etc. By 
considering 20% of water in the formula, the maximum loading capacity of insulin would 
be about 10-11 IU/mL which may not be sufficient for the human dose. Also, such a high 
percentage of the lipid phase may cause several problems after nasal delivery 17. Another 
study reported by Mitra et al. have used both o/w and o/w lipid micelles.  However, w/o 
micelles did not show any improve in the PK parameters which was in contrast with w/o 
SEN reported by Sintov et al. And the insulin in o/w micelles only increased the AUC0-120 
for 1.5-fold as compared to insulin in buffer at 5 IU/kg 87. It can be seen that the 
developed SEN containing FAME can overcome these issues with the higher 
improvement in relative BA. 
In addition to the emulsion system, the most successful delivery techniques for 
intranasal delivery of insulin have been cyclodextrin and cationic polymer, chitosan. The 
use of cyclodextrin for intranasal delivery of insulin has been studied for decades 88. 
Various types of cyclodextrin have been developed to overcome their toxicity and to 
improve their drug loading capacity. The most successful cyclodextrin system was 
insulin-loaded dimethyl-β-cyclodextrin which resulted in 108% relative BA as compared 
to s.c. injection in rats without any toxicity observed. However, the relative BA of the 
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same formulation was found to be 0% in rabbits and humans 89. The correlation between 
animal model and human for cyclodextrin was found to be very low. 
Chitosan is a cationic polysaccharide which has been used to enhance insulin 
absorption across the nasal route by forming nanoparticles or as a permeation enhancer. 
Nanoparticles for insulin did not appear to effectively improve insulin absorption and the 
insulin-loading capacity remained limited, while the addition of chitosan (0.5%) into 
insulin solution improved the relative BA to 48% in rats and 4% in sheep as compared to 
S.C 15, 75, 90. The permeation enhancing effect of chitosan was concentration dependent 
and the mechanism of enhancement was the reversible interaction between chitosan with 
the tight junctions due to the positive charge of chitosan at the pH below its pKa of 6.5. 
Illum et al. reported many clinical trials (> 700 human volunteers and patients) have been 
on nasal formulations containing chitosan, but there are no nasal products reaching the 
market either for small molecules to proteins like insulin 15. One of the possible reasons is 
that the charge of the mucus layer on the epithelium is also a negative charge which can 
bind with chitosan before the chitosan molecule can interact with the tight junctions of 
the epithelium layer. However, SEN with the size below 100 nm and the zeta potential 
from neutral to -10 mV has been reported to exhibit the capability to penetrate across 
mucus layer 91. Together with the results of Chapter 3 on Calu-3 monolayer which 
exhibits mucus layer, it can be inferred that the permeation enhancement of the developed 
SEN containing FAME on insulin is not affected by the mucus layer presented in the 





SEN containing G8/10MD could significantly enhance insulin absorption through 
intranasal delivery, which was dependent on the concentration of the preconcentrate in 
the SEN. The SEN containing G8/10MD (from 5-20% preconcentrate) did not cause 














































Figure 20 Blood glucose levels (% of initial) following s.c. (1 IU/kg) and i.n. (3 IU/kg) 
administration of insulin to streptozotocin-induced diabetic rats. (■) s.c. insulin solution; 
(△) i.n. insulin in 20SEN; (✕) i.n. insulin in 10SEN; (▲) i.n. insulin in 5SEN; (○) i.n. 



















































Figure 21 Plasma insulin-time profiles following s.c. (1 IU/kg) and i.n. (3 IU/kg) 
administration of insulin formulations to streptozotocin-induced diabetic rats. (■) s.c. 
insulin solution; (△) i.n. insulin in 20SEN; (✕) i.n. insulin in 10SEN; (▲) i.n. insulin in 
5SEN; (○) i.n. insulin solution; (●) i.n. insulin in 1% SLS solution; and (□) i.n. PBS 
























133.6 ± 8.5 82.8 ± 62.5 100 100 
































5SEN 53.2 ± 17.6 5.0 ± 
0.0 
168.5 ± 52.3 21.8 ± 15.8 42.0 ± 
13.0* 
8.8 ± 6.4 
Insulin 
solution 
13.5 ± 6.7 15.0 ± 
0.0 
5.44 ± 24.7 10.0 ± 4.8 1.4 ± 6.1 4.0 ± 1.9 
PBS 
 
N/A N/A 0.0 ± 25.2 N/A 0.0 ± 6.3 N/A 
Each value represents the mean ± SEM (n=3-4); SC dose = 1 IU/Kg; treatment 3 IU/Kg  
Cmax: maximum insulin concentration; Tmax: time to reach Cmax; AAC: area above the glucose-
time curve; AUC: area under the insulin-time curve; PA: relative pharmacological availability 
compared with s.c; BA: relative bioavailability compared with s.c. 
*: Significantly higher than insulin solution; **: Significantly higher than SLS; ***: Significantly 
higher than S.C.; # Significantly higher than 20SEN; ##: Significantly higher than 10SEN; ###: 
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Figure 22 Photomicrographs of nasal epithelium in rat nasal cavities (section II) 
following intranasal administration of (A) insulin solution; (B) insulin in 10SEN; (C) 
insulin in 20SEN; and (D) insulin in 1% SLS solution (positive control). S: Septum; OE: 
Olfactory Epithelium; RE: Respiratory Epithelium; NC: Nasal Cavity; L-NC: Left Nasal 































































Figure 23 Comparison of olfactory epithelium in rat nasal cavities following intranasal 
administration of (A) insulin solution; (B) insulin in 10SEN; (C) insulin in 20SEN; and 
(D) insulin in 1% SLS solution (positive control). L-NC: Left Nasal Cavity; R-NC: Right 



















































Figure 24 Comparison of respiratory epithelium in rat nasal cavities following intranasal 
administration of (A) insulin solution; (B) insulin in 10SEN; (C) insulin in 20SEN; and 
(D) insulin in 1% SLS solution (positive control). L-NC: Left Nasal Cavity; R-NC: Right 






SUMMARY OF THE STUDY AND CONCLUSION 
5.1. Summary of The Study 
The objective of the present study is to investigate the permeation enhancing 
property and safety of SEN, particularly the fatty acid esters (FAEs) when formulated in 
SEN, and use these findings to enhance insulin absorption through the nasal route. 
Chapter 1 was to identify the factors affecting cytotoxicity and permeation 
enhancement of SEN on Madin-Darby Canine Kidney (MDCK) cells, a widely used 
paracellular model. The twenty-six FAEs commonly used in SEN were investigated. The 
results demonstrate that, among the FAEs (mono-, di-, and triesters), the fatty acid 
monoester (FAME) is the main excipient causing concentration-dependent cytotoxicity 
and opening of tight junction. When FAME was formulated in SEN, the cytotoxic of 
FAME was reduced with the presence of triglycerides, the increase in droplet size, and 
the higher intermolecular interaction within lipid droplets. Therefore, four FAMEs 
including G8/10MD, G18:1M, G18:2MD and PEG8/10MD were selected to formulate 
SEN with triglyceride and further evaluated for their capability to enhance insulin across 
the opened tight junctions in cell culture study in Chapter 2. 
Chapter 2 was to evaluate the efficacy and toxicity of the developed SEN for the 
transport of insulin across cell monolayer in vitro. The coadministration of insulin in the 
aqueous phase of SENs containing G8/10MD, G18:2MD, PEG8/10MD could 
significantly (p<0.05) enhance the transport of insulin across the human airway epithelial 
cell monolayer (Calu-3). The SEN containing G8/10MD at non-toxic concentration 
showed the highest permeation-enhancing effect on insulin as compared to the other 
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FAMEs. The SEN containing G8/10MD enhance the transport of insulin by 
compromising the tight junctions, and the tight junction integrity was recovered after 12 
hours. The co-administered of insulin with SEN containing G8/10MD can prevent the 
fibril formation of insulin. Therefore, SEN containing G8/10MD was selected to further 
evaluate in ex vivo and in vivo studies in Chapter 3 and 4, respectively. 
Chapter 3 was to investigate the efficacy and toxicity of the developed SEN for 
the transport of insulin across bovine nasal mucosa ex vivo. The 2-h transport of insulin 
across the nasal mucosa from both anterior and posterior regions was enhanced by 
20SEN (20% of preconcentrate), while the 10SEN (10% of preconcentrate) did not 
enhance the transport of insulin. The 20SEN caused minimum nasociliotoxicity on the 
bovine nasal mucosa, while no toxicity was observed with the 10SEN. Therefore, 20SEN 
was used as the highest concentration in the further in vivo study. 
Chapter 4 was to study the efficacy and toxicity of the developed SEN for i.n. 
delivery of insulin in streptozotocin-induced diabetic rats. As compared to s.c. injection 
of insulin solution, the relative PA achieved by 20SEN, 10SEN, and 5SEN were 57-, 42-
and 30-fold higher than the solution form (1.4 ± 6.1%), respectively. The relative PA by 
20SEN was also significantly (p<0.05) higher than that by the SLS solution (33.9 ± 
8.9%). The 20SEN, 10SEN and 5SEN also increased the relative BA by 8.5-, 3.8-, and 
1.2-fold higher than that by the solution form, respectively. The relative BA of i.n. insulin 
in 20SEN was also significantly higher (p<0.05) than insulin in 5SEN. Both 
pharmacokinetic and pharmacodynamic results showed that SEN containing G8/10MD 
could significantly (p<0.05) enhance the insulin absorption through intranasal delivery, 
which was dependent on the concentration of the preconcentrate in the SEN. The SEN 
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containing G8/10MD (from 5-20% preconcentrate) did not cause toxicity on the nasal 
epithelium. 
In conclusion, the factors affecting cytotoxicity and permeation enhancement of 
SEN were elucidated. The coadministration of insulin in the aqueous phase of SEN 
containing FAMEs was verified for the efficacy of the transport of insulin across cell 
monolayer, in vitro. SEN containing G8/10MD was also verified for their safety and the 
capability to enhance insulin absorption across bovine nasal mucosa, ex vivo, and 
streptozotocin-induced diabetic rats, in vivo. 
 
5.2. Conclusion 
Self-emulsified nanoemulsion (SEN) containing medium-chain monoglyceride 
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